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ABSTRACT 
 
The proton-coupled oligopeptide transporter PEPT1 has recently been linked to 
intestinal inflammation and inflammatory bowel disease (IBD) because of its ability to 
transport bacterial peptides (e.g., Tri-DAP, MDP, fMet-Leu-Phe) and its aberrant 
expression in the colon of IBD patients. Although studies have demonstrated that several 
bacterial peptides were substrates of PEPT1, the relative importance of this protein (as 
compared to other transporters and pathways) and its regional permeability have not been 
addressed. Therefore, the first objective of this dissertation focused on the importance of 
intestinal PEPT1 in transporting a bacterially-produced chemotactic peptide, fMet-Leu-
Phe, using the in situ single-pass intestinal perfusion (SPIP) technique in wild-type and 
Pept1 knockout mice. The results demonstrated that PEPT1 contributed about 80-90% of 
fMet-Leu-Phe transport in the small intestine and showed saturable and low-affinity 
kinetics (Km = 1.6 mM). The contribution of PHT1 was ruled out due to the lack of 
inhibition of fMet-Leu-Phe transport by L-histidine. The significance of fMet-Leu-Phe 
transport could be translated from kinetic to dynamic effects. Using a modified intestinal 
perfusion condition, the activity of myeloperoxidase (MPO), a marker for neutrophil 
migration, was increased by perfusing fMet-Leu-Phe in the jejunum of wild-type mice. In 
contrast, MPO activity showed no increase when perfusing fMet-Leu-Phe in the jejunum 
of Pept1 knockout mice. These findings suggested that PEPT1 was the major transporter 
 xv 
 
for the transport of fMet-Leu-Phe in the small intestine and could influence the induction 
of inflammation.   
Lys-Pro-Val has been suggested as a potential therapeutic agent for IBD due to its 
anti-inflammatory effects in mouse colitis models. However, some important properties 
(e.g., intestinal permeability and stability) have not been studied. Therefore, the second 
objective of this dissertation was to study the transport properties of the anti-
inflammatory tripeptide Lys-Pro-Val using the intestinal perfusion technique in wild-type 
and Pept1 knockout mice. The results showed that PEPT1 was responsible for at least 
90% of Lys-Pro-Val uptake in the small intestine and exhibited saturable transport with 
relatively high affinity (Km = 0.11 mM). The potential contribution of other transporters 
(e.g., PHT1, OCT, PAT1) was not evident because no inhibition of Lys-Pro-Val transport 
was observed by substrates of these transporters. These findings suggested that PEPT1 
was the major transporter in transporting Lys-Pro-Val in small intestine. The results of 
intestinal stability studies suggested that Lys-Pro-Val was not enzymatically stable in the 
intestinal lumen and that major metabolism took place in the jejunum and ileum.  Taken 
together, although Lys-Pro-Val may be a good candidate to treat IBD through the 
aberrant expression of colonic PEPT1, drug stability was a significant concern for oral 
administration.   
In conclusion, results from this dissertation suggested that PEPT1 could transport 
bacterial peptides, implying that aberrant expression of PEPT1 in the colon may 
contribute to the progression of IBD. Although colonic PEPT1 may also serve as a drug 
targeting (delivery) opportunity for some bioactive peptides, such as Lys-Pro-Val to treat 
IBD, intestinal stability of this substrate is a realistic concern. 
1 
 
Chapter 1 
 
RESEARCH OBJECTIVES 
 PEPT1 belongs to the proton-coupled oligopeptide transporter (POT) family. 
According to the HUGO Gene Nomenclature Committee (HGNC), PEPT1 is categorized 
under the Solute Carrier family 15 (SLC15). So far, there have been four mammalian 
members recognized within this family: PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 
(SLC15A4), and PHT2 (SLC15A3). PEPT1 has been considered an important transporter 
because of its absorption of di/tripeptides, primarily from the breakdown products of 
protein in the digestive tract. In addition to its physiological importance in protein 
absorption, PEPT1 also has pharmacological importance because of its ability to transport 
a variety of peptidomimetic drugs. Due to the broad spectrum of substrate specificity and 
its importance in intestinal absorption, PEPT1 has been utilized as a drug delivery target 
in order to improve the bioavailability of poorly absorbed compounds. The impact and 
influence of transporters in drug absorption, disposition, elimination, drug-drug 
interactions, and disease-related pathogenesis have also received increasing attention.  
For example, PEPT1 has been shown to be regulated by several endogenous and 
exogenous factors (e.g., hormones, growth factor, 5-fluorouracil, and cyclosporine). More 
interestingly, under some disease conditions (i.e., inflammation), PEPT1 exhibited an 
aberrant expression and up-regulation in the colon.   
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Inflammatory bowel disease (IBD) was recently linked to PEPT1 for several 
reasons. First, in colonic biopsies of patients with IBD, it was demonstrated that PEPT1 
was up-regulated in the apical membrane of colon. Second, it was shown that PEPT1 has 
the ability to transport some bacterially-produced peptides which can exacerbate 
inflammation. Third, one of the ligands of the NOD2 receptor, muramyl dipeptide (MDP), 
has been shown to be a substrate of PEPT1. Since the NOD2 gene was the first gene 
associated with an IBD phenotype, the fact that PEPT1 could transport its ligand was 
believed to be strong supportive evidence. Although it has been suggested that PEPT1 
was associated with IBD, the true function and role of PEPT1 in the pathogenesis of IBD 
is still uncertain. A polymorphism study recently revealed that a SNP in the PEPT1 gene 
(Ser117ASN) showed association with Crohn’s disease (CD) susceptibility in two 
populations in opposed directions (risk and protection, respectively).          
 Among different experimental models, the genetic knockout mouse model 
provides a great opportunity and tool to study the contribution and impact of PEPT1 in 
substrate absorption, disposition, pharmacology and, perhaps, pathology. Previously, our 
laboratory has successfully demonstrated the value of using Pept2 knockout mice to 
study the importance of PEPT2 in renal drug reabsorption and of using Pept1 knockout 
mice to study the contribution of PEPT1 in intestinal drug absorption in vitro, in situ, and 
in vivo. Although studies have demonstrated that several bacterial peptides (e.g., Tri-DAP, 
MDP, fMet-Leu-Phe) were substrates of PEPT1, the relative importance of this protein 
(as compared to other transporters and pathways) and the regional permeability have not 
been addressed. Therefore, the first objective of this dissertation was to use Pept1 
knockout mice to study the importance of PEPT1 in transporting a bacterial peptide, 
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fMet-Leu-Phe, by using the in situ single-pass perfusion technique. The specific aims 
were: 1) to study the importance of intestinal PEPT1 in transporting fMet-Leu-Phe, 2) to 
determine the regional permeability of fMet-Leu-Phe, and 3) to study the functional 
dynamics (i.e., effect on neutrophil migration) of transporting fMet-Leu-Phe into 
enterocytes.  
 Several bioactive peptides have attracted interest because of their 
pharmacological potential in treating intestinal inflammation. Lys-Pro-Val is one such 
example that has recently drawn attention. Lys-Pro-Val is a bioactive tripeptide, derived 
from -melanocyte-stimulating hormone (-MSH). Studies have demonstrated that Lys-
Pro-Val exhibited promising anti-inflammatory activity in different models. Recent 
reports have also considered Lys-Pro-Val as a potential therapeutic opportunity for the 
treatment of IBD. Although Lys-Pro-Val has been shown to be a substrate of PEPT1 in 
Caco-2 cells, the direct measurement of its intestinal permeability in a relevant 
mammalian model has not been demonstrated. Furthermore, the stability of Lys-Pro-Val 
in the intestine has not been addressed. Therefore, the second objective of this 
dissertation was to study the intestinal transport of Lys-Pro-Val using an in situ single-
pass intestinal perfusion technique in both wild-type and Pept1 knockout mice. The 
specific aims were: 1) to determine the intestinal permeability of Lys-Pro-Val, 2) to study 
the regional permeability in the PEPT1-mediated transport of transporting Lys-Pro-Val, 
and 3) to study the intestinal stability of Lys-Pro-Val using intestinal homogenates.  
 Several important findings have been provided from this dissertation. First, the 
results have demonstrated that fMet-Leu-Phe has substantial permeability in the 
duodenum, jejunum and ileum, but not colon, of wild-type mice and that this translates 
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into a greater neutrophil migration in jejunum than that observed in Pept1 knockout mice.  
This provides solid evidence for a role of intestinal PEPT1 in the transport of a 
bacterially-produced chemotactic peptide and subsequent inflammatory effects.   Second, 
the anti-inflammatory tripeptide Lys-Pro-Val also has marked transport by intestinal 
PEPT1 in all regions of the small intestine (but not colon).  However, its instability in the 
intestine precludes its use as an effective tool against inflammation in IBD patients after 
oral dosing. 
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Chapter 2 
 
BACKGROUND AND LITERATURE REVIEW 
 
PROTON-COUPLED OLIGOPEPTIDE TRANSPORTERS 1  
 
Description 
 Proton-coupled oligopeptide transporters 1 (PEPT1) is categorized under solute 
carrier family 15 (SLC15) according to the HUGO Gene Nomenclature Committee 
(HGNC) system. Four members have been identified so far in this family, which includes 
PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLC15A4), and PHT2 (SLC15A3). 
PEPT1 is the first peptide transporter cloned from the rabbit intestine cDNA library (Fei 
et al., 1994) in 1994. Since then, PEPT1 have been cloned from several other 
mammalians, including human (Liang et al., 1995), monkey (Zhang et al., 2004a), rat 
(Saito et al., 1995; Miyamoto et al., 1996), mouse (Fei et al., 2000), pig (Klang et al., 
2005), and sheep (Pan et al., 2001). In general, they shared high degree of sequence 
homology across species (~ 80% identity). Comparing to the amino acid sequence of 
human PEPT1, they were 92%, 83%, 83%, 82.8%, 83%, 81% identities for monkey, rat, 
mouse, pig, sheep, and rabbit, respectively. Indeed, PEPT1 was one of the archaic 
transporters recognized with high conservation from prokaryotes to eukaryotes (Daniel et 
al., 2006). The human PEPT1 gene is located on chromosome 13q33-34 and encodes 708 
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amino acids. Unlike high homology across species, PEPT1 shares around 50% amino 
acid identity with PEPT2, another peptide transporter that cloned from human kidney 
cDNA library in 1995 (Liu et al., 1995). PEPT2 gene is located on chromosome 3 and 
encodes 729 amino acids in human. PEPT1 and PEPT2 transporters share many common 
features, however, the major distinction between both is from the kinetic characteristic, 
that is, PEPT1 is considered as a low affinity and high capacity transporter, whereas 
PEPT2 is considered a high affinity and low capacity transporter. Two additional peptide 
transporters, PHT1 (Yamashita et al., 1997) and PHT2 (Sakata et al., 2001) were cloned 
from the rat brain cDNA library in 1997 and 2001, respectively. PHT1 and PHT2 genes 
encode 572 and 582 amino acids and they shared less than 20% amino acid identity to 
PEPT1 and PEPT2 and they have been demonstrated to transport not only di/tripeptides, 
but also a single amino acid, L-histidine, in a proton dependent fashion. Unlike PEPT1 
and PEPT2, there were less studies on PHT1 and PHT2 regarding to their function, 
importance and substrate specificity, however, recently, studies have shown that PHT1 
(SLC15A4) was important in the toll-like receptor 9 (TLR9) and NOD1 signaling and 
associated with inflammatory bowel diseases and systemic lupus erythematosus (Han et 
al., 2009; Sasawatari et al., 2011).  
 
Molecular Structure  
 The molecular structure of PEPT1 has been demonstrated by the hydropathy 
analysis of the amino acid sequence. 12 putative transmembrane domains (TMD) with 
both N- and C- termini facing the cytosol and a large hydrophilic loop presented between 
TMD9 and TMD10 have been predicted. For human PEPT1, from the amino acid 
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sequence, 7 putative N-linked glycosylation sites, 2 protein kinase C-dependent 
phosphorylation sites (Ser-357, Ser-704), but none of protein kinase A-dependent 
phosphorylation site (Liang et al., 1995). Similarly, in mouse PEPT1, 6 putative N-linked 
glycosylation sites, 1 protein kinase C-dependent phosphorylation site (Ser-357), and 1 
protein kinase A-dependent phosphorylation site (Thr-362) has been suggested (Fei et al., 
2000). Regarding to the putative promoter regions, both human and mouse PEPT1 were 
lack of classical TATA box element presented in the -30 to -90 bp upstream position 
nearby the transcription start site. Instead, a TATA box-like sequence, CAATAAATA, 
was present at a farther upstream position of mouse PEPT1 (-813). For human PEPT1, 
two TATA boxes were present at unusual positions 511 bp and 571 bp upstream from the 
transcription start site. Therefore, the GC box was believed to be the primarily regulatory 
sites for PEPT1 transporter. Three GC-rich boxes (-88, -322, -352 bp) and one at -29 bp 
and several others within -300 bp were identified in mouse and human PEPT1, 
respectively (Fei et al., 2000; Urtti et al., 2001).   
 
Importance  
 PEPT1 has an indispensable role in the absorption of protein. Before the 
discovery of PEPT1, it was first believed that the dietary proteins were not absorbed until 
hydrolysis to the form of free amino acids. However, several studies have demonstrated 
evidence that proteins were absorbed mainly in the form of small peptides rather than 
single amino acids. Adibi and Mercer found that after the subjects fed with a meal 
containing 50 g bovine serum albumin, the concentration of peptide-bound amino acids 
in the lumen of the small intestine was greater than that of amino acid in free form (Adibi 
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et al., 1973). Nixon and Mawer also found that after feeding test meals, the free amino 
acid concentrations in the intestinal lumen correlated poorly to the concentration of the 
free amino acid in the acid hydrolysates of test meals, which suggesting that hydrolyzed 
peptides might directly be absorbed from the intestine (Nixon et al., 1970). Latter studies 
further showed that intact dipeptides could be detected in the mesenteric plasma (Boullin 
et al., 1973) and amino acids and di/tripeptides have different mechanisms of absorption, 
showing different Vmax and Kt. In general, (1) di/tripeptides showed higher absorption 
rate in proximal small intestine than that in distal small intestine; (2) free amino acid 
showed higher absorption rate in distal small intestine than that in proximal small 
intestine; (3) the absorption rate of di/tripeptides was higher than that of free amino acid 
(Matthews et al., 1968; Crampton et al., 1973; Matthews, 1975). After the discovery of 
PEPT1, more specific and extensive studies have been performed and well accepted that 
PEPT1 is the major transporter responsible for the absorption of dietary protein in the 
form of di/tripeitdes. The concentration of peptide-bound amino acid could achieve as 
high as 80% of the total amino acids and get absorbed by PEPT1 (Ganapathy et al., 2006).   
 The importance of PEPT1 was highlighted in some genetic disorder diseases. 
Hartnup disease is a recessive genetic disorder, which affects the intestinal and renal 
transport of neutral amino acids (alanine, serine, threonine, valine, leucine, isoleucine, 
histidine, glutamine, asparagines, phenylalanine, tyrosine, and tryptophan) (Leny, 2001). 
Recent studies identified the B
0
AT1 transporter (system B
0
) was defective in the patients 
of hartnup disease (Kleta et al., 2004; Seow et al., 2004). Cystinuria is the other genetic 
defect in system b
0,+
 resulted in a dysfunction of transport of cationic amino acids 
(arginine, lysine, and ornithine) and cystine (Palacin et al., 2001b). The gene that 
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responsible for this defect were also recognized as rBAT (Type I) or b
0,+
AT (Non-type I) 
(Palacin et al., 2001a). Surprisingly, patients with these genetic defects did not exhibit 
any obvious symptoms or evidence of protein malnutrition. The answer was unclear until 
studies found out that the affected amino acids were absorbed adequately in the form of 
small peptides (Asatoor et al., 1970; Hellier et al., 1970). Hellier showed that the 
absorption of lysine was compromised in cystinuric patient, but the absorption of glycy-
L-lysine was similar to normal subject (Hellier et al., 1970), which again supported that 
PEPT1 was very important in the absorption of dietary protein especially in certain 
genetic disorders.             
 PEPT1 has not only nutritional importance but also pharmacological relevance 
because studies have shown that some peptidomimetic drugs, such as β-lactam antibiotics 
(Okano et al., 1986), ACE inhibitors (Thwaites et al., 1995), renin inhibitors (Kramer et 
al., 1990), anticancer drug bestatin (Tomita et al., 1990), and antiviral prodrug 
valacyclovir (Ganapathy et al., 1998), were the substrates for PEPT1. With the fact that 
PEPT1 transporter could accommodate compounds with various physicochemical 
characteristics in size, charge, polarity, and structure flexibility, a prodrug strategy 
targeting for PEPT1 has been widely used in the pharmaceutical industry (Rubio-Aliaga 
et al., 2002). Successful examples were like valacyclovir, val-ganciclovir, and L-Pro-L-
Phe-Alendronate. The bioavailability as supposed to their parent compounds was 
increased 3-5 fold, 10 fold, and 3 fold, respectively (Beauchamp et al., 1992; Jung et al., 
1999; Ezra et al., 2000).    
 Since PEPT1 also expressed in kidney (Lu et al., 2006) (especially in rat), the 
importance of PEPT1 in the renal reabsorption has been studied as well. However, 
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PEPT1 has been shown to be less important than PEPT2 with regard to the reabsorption 
of the peptide-bound amino nitrogen and peptidomimetic drugs in kidney. Studies using 
Pept2 knockout mice revealed that PEPT2 was more important than PEPT1 in kidney for 
the reabsorption of two known substrates (for Gly-Sar, PEPT2 contributed for 86% and 
PEPT1 accounted for 14% of total reabsorption; for cefadroxil, PEPT2 accounted for 
95% and PEPT1 only contributed for 5% of total reabsorption) (Ocheltree et al., 2005; 
Shen et al., 2007). 
 
Tissue Distribution and Cellular Localization 
 Although PEPT1 widely expressed in several tissues, the mRNA expression of 
PEPT1 primarily focused in the small intestine region of the digestive tract (Lu et al., 
2006). The protein expression of PEPT1 agreed with the mRNA that PEPT1 
predominately expressed in the small intestine rather than in large intestine of digestive 
tract (Ogihara et al., 1996; Jappar et al., 2010). In the small intestine, PEPT1 has been 
shown to express mostly in the absorptive epithelial cell on the tip of the villi and very 
less amount in the crypt and the goblet cell. The expression of PEPT1 was limited to the 
apical membrane of epithelial cells (Ogihara et al., 1996; Walker et al., 1998; Groneberg 
et al., 2001). The expression of PEPT1 in kidney was species dependent. PEPT1 have 
been shown to locate at the apical membrane of S1 segment of renal proximal tubule in 
rat (Shen et al., 1999). However, in other species, such as rat and human, PEPT1 showed 
low expression level in kidney (Lu et al., 2006; Hilgendorf et al., 2007).   
 PEPT1 recently has been found to express in human macrophages isolated from 
human peripheral blood and a monocytic cell line, KG-1. Although the characteristic 
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function of PEPT1 in immune cell showed slightly different from PEPT1 expressed in 
epithelial cell (the maximal activity presented at physiological pH, 7.2 as opposed to 
epithelial cell at acidic environment, around pH 6.2), this expression might imply the 
importance of PEPT1 in the innate immunity (Charrier et al., 2006a). Other tissues, such 
as liver, pancreas, lung, bile duct, ovary, placenta, testis, prostate, mammary gland, nasal 
epithelium, and placenta, have been shown to express some level of PEPT1 mRNA. 
However, because there was little information available for these tissues, less was known 
about the function of PEPT1 in these tissues (Herrera-Ruiz et al., 2001; Knutter et al., 
2002; Lu et al., 2006; Gilchrist et al., 2010; Agu et al., 2011).  
Interestingly, PEPT1 has been found to express not only in the plasma membrane 
but also in the membrane of the subcellular organelle. The lysosomal localization of 
PEPT1 has been shown in renal cells and acinar cells in exocrine pancreas, which 
suggesting a transport phenomenon occurred to prevent the accumulation of incomplete 
digested peptides in lysosome (Bockman et al., 1997; Zhou et al., 2000).   
 
Structure Function Relationship        
 Up to date, only the crystal structure of a prokaryotic homologues, PepT(So) from  
the bacterium Shewanella oneidensis, has been resolved (Newstead et al., 2011). 
However, with the absence of the exact structure of mammalian PEPT1 transporter, many 
other alternative methods have been used to elucidate the structure function relationship 
such as epitope insertion method, site-directed mutagenesis approach, chimeric 
construction, substituted-cysteine accessibility method (SCAM) and computer modeling 
technique. Based on the hydropathy analysis of amino acid sequences, PEPT1 has been 
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suggested to contain 12 transmembrane domains (TMD). The membrane topology model 
has been confirmed and supported by an epitope insertion study (Covitz et al., 1998). 
Doring constructed a chimeric protein consisted of PEPT2 N- terminal region (1-401) and 
PEPT1 C- terminal region (402-707) and found that the chimeric protein behaved more 
like PEPT2 than PEPT1 in terms of substrate specificity and affinity, indicating that the 
substrate binding region might reside in the region before TMD9 (Doring et al., 1996), 
rather than in the large extracellular loop between TMD9 and TMD10. More chimeric 
proteins were made and further pointed out the putative substrate binding site was located 
between TMD7-9 and TMD1-6 were involved in the determination of pH dependency 
and the major part of substrate-binding pocket (Fei et al., 1998; Terada et al., 2000a).   
 Site-directed mutagenesis studies have revealed the essential amino residues of 
PEPT1. At first, three highly conserved histidyl residues of PEPT1 across species, His-57, 
His-121, and His-260 have been studied. Terada demonstrated that after the mutation of 
His-57 and His-121, the uptake of Gly-Sar and ceftibuten were abolished, suggesting that 
these two histidyl residues were crucial and involved in substrate recognition of rat 
PEPT1 (Terada et al., 1996). In contrast to rat PEPT1, only His-57 residue seemed to 
have an obligatory role for the function of human PEPT1 (Fei et al., 1997). Latter studies 
have suggested that His-57 reside might serve as the proton binding site for PEPT1 to 
initiate the transport (Chen et al., 2000; Uchiyama et al., 2003). A number of other 
mutations have been studied to demonstrate some function-related residues other than 
conserved histidyl residues. Tyr-56 and Tyr-64 have been shown to be indispensible for 
the normal function of PEPT1. The mutation of Tyr-56 and Tyr-64 resulted in a complete 
loss of function. Since they were both neighboring residues to His-57, one explanation 
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has been proposed that Tyr-56 and Tyr-64 were involved in the stabilization of positive 
charges within the membrane electric field (Chen et al., 2000). Arg-282 and R-361 were 
other examples of critical residues for the function of PEPT1. After the mutation of either 
Arg-282 or R-361, the uptakes of D-Phe-L-Gln or GlySar were significantly 
compromised and Meredith and his coworkers proposed a charge pair model between 
Arg-282 and R-361 (Meredith, 2004; Kulkarni et al., 2007; Pieri et al., 2008). Another 
study also showed supportive data that Arg-282 and R-361 were forming a charge pair 
(electrostatic gate) between TMD7 and 8 of PEPT1 (Bossi et al., 2011).   
   Substituted-cysteine accessibility method (SCAM) is another method to study 
the structure of transporter, especially to determine the relative orientation, functional 
importance, and solvent accessibility of the transmembrane segments of transporter 
(Liapakis et al., 2001). Kulkarni has employed this method to elucidate the structural 
information of TMD5 (Kulkarni et al., 2003a) and TMD7 (Kulkarni et al., 2003b). In 
general, TMD5 lined slightly tilted along the putative aqueous channel with the exofacial 
half forming a classical amphipathic -helix and the cytoplasmic half being highly 
solvent accessible. TMD7, however, is relatively solvent-accessible along most of its 
length, particularly on the intracellular end. Upon substrate binding, TMD7 might shift to 
allow the opening of channel and translocation of substrate. TMD3 has been also studied 
by Links using SCAM. TMD3 was proposed to slightly tilting to substrate translocation 
pathway similarly to TMD5 and TMD 7 and would interact with TMD5 with limited 
solvent accessibility in the extracellular region and relatively solvent accessible in the 
intracellular region (Links et al., 2007). Several crucial amino acid residues have been 
identified as well, such as Tyr-167, Asn-171, and Ser-174 in TMD5, Phe-293, Leu-296, 
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and Phe-297 in TMD7, and Thr-83, Leu-87, Ser-88, Tyr-91, Gly-94 and Ser-101 in 
TMD3. The uptake of Gly-Sar of all of the mutations significantly reduced to < 25% of 
that of wild-type.    
 Computer modeling approach has been applied to predict the structure function 
relationship of PEPT1. Bolger has successfully proposed a computer simulated model for 
PEPT1 based on the energy minimization and molecular dynamics simulation (AMBER) 
algorithm. The putative model was then submitted to the substrates (Gly-Gly and Gly-
Gly-Gly) interaction analysis by MIDAS and DOCK. Several hypothesized residues were 
proposed and confirmed by site-directed mutagenesis approach. Tyr-167, Trp-294, and 
Glu-595 have been shown to be important for the function of PEPT1 (Bolger et al., 1998). 
 
Structure Activity Relationship 
 Since PEPT1 has been shown to transport a number of peptidomimetic drug , such 
as β-lactam antibiotics (Okano et al., 1986), ACE inhibitors (Thwaites et al., 1995), renin 
inhibitors (Kramer et al., 1990), anticancer drug bestatin (Tomita et al., 1990), and 
antiviral prodrug valacyclovir (Ganapathy et al., 1998), PEPT1 has been considered as a 
promising drug delivery target to increase the bioavailability of poorly absorbed drugs 
(Terada et al., 2004). In order to develop a better candidate targeting to PEPT1 
transporter, the structural requirements for transport via PEPT1 have been extensively 
studied (Brodin et al., 2002; Brandsch et al., 2004). However, most of studies performed 
by a traditional competition assay, which reported the inhibition (affinity) constant Ki (or 
IC50) of a test compound to a known substrate (e.g. [
14
C]Gly-Sar). Therefore, to interpret 
the affinity data should always bear in mind that they were not actual transport. Brandsch 
 15 
 
and his group provided the criteria to classify the substrates based on the affinity constant 
(Ki). Ki values < 0.5 mM as high affinity, 0.5 – 5 mM as medium affinity and > 5 – 15 
mM as low affinity. 
 The actual transport of PEPT1 substrate could be monitored by two experimental 
methods; both were based on the characteristic of PEPT1 transport, electrogenicity. Two 
electrode voltage clamp technique in PEPT1 expressing Xenopus oocytes could measure 
the inward current evoked along the translocation of substrate (Fei et al., 1994). The 
other method was developed recently by Smith and his group. The method used a 
membrane potential-sensitive fluorescent dye (MP) to indicate the occurrence of transport 
event (Faria et al., 2004). Since different experimental setting and data analysis, they 
provided different criteria for the classification of substrate. A parameter 
%GlySarmax/EC50 was used and the classification as following: best substrates > 1000, 
good substrates = 300-1000, intermediate substrates = 100-300, and poor substrates = 0-
100 (% GlySarmax: maximum activation relative to Gly-Sar) (Vig et al., 2006).  
 
The physicochemical properties of potential substrates were listed below: 
 Size: There was no common agreement for the maximal molecular weight that 
PEPT1 could transport. Generally speaking, candidate substrates need to be large than 
single amino acid and smaller than tetrapeptides. However, the distance between N- and 
C- termini influence more than the molecular weight. The optimal length was estimated 
about 5.5 Å (= 550 pm) by Li, and confirmed by Doring that the distance between N- and 
C- termini should fall between 5.0 to 6.35 Å (= 500 to 635 pm) (Li et al., 1996; Doring et 
al., 1998b).  
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 Stereospecificity: PEPT1 was markedly stereochemically specific in substrate 
transport. L-configuration of each amino acid was preferable. The rank of affinity for 
PEPT1 in Caco2 cell was L-Val-L-Val > D-Val-L-Val > L-Val-D-Val > D-Val-D-Val 
and L-Val-L-Val-L-Val > L-Val-L-Val-D-Val > D-Val-L-Val-L-Val > D-Val-D-Val-L-
Val > L-Val-D-Val-L-Val > D-Val-L-Val-D-Val, L-Val-D-Val-D-Val, D-Val-D-Val-D-
Val (no affinity) shown by Li (Li et al., 1998). Meredith also showed similar results on 
tripeptide Ala-Ala-Ala by PEPT1 expressing Xenopus oocytes as L-Ala-L-Ala-L-Ala > 
L-Ala-L-Ala-D-Ala > D-Ala-L-Ala-L-Ala > L-Ala-D-Ala-L-Ala (Meredith et al., 2000). 
Interestingly, the low affinity of D-configured peptide could be resolved by the side chain 
modification. D-Asp(OBzl)-Ala, a β-esterified dipeptide showed remarked affinity to 
PEPT1 (IC50 = 2.62 mM). It provided a solution to generate an enzymatically stable 
peptide while retaining a comparable affinity to PEPT1(Taub et al., 1997). 
 Terminal groups: Generally speaking, modification of either N- or C- terminal 
groups would result in the decrease of affinity to PEPT1 (Meredith et al., 2000). 
However, both N- or C-terminal groups were not absolutely essential for affinity and 
transport. Dipeptides with N-methylation Sar-Pro showed decrease but still comparable 
affinity as compared to Gly-Pro (Ki from 0.16 to 2.5 mM) (Brandsch et al., 1999). 
However, an exception has been demonstrated when modifying N- terminal group with 
fatty acid (C4-Phe-Gly and C6-Phe-Gly). The affinity of the compound with modification 
increase comparing to parent compound (Fujita et al., 1997). C- terminal modification of 
peptide was more tolerable than N- terminal modification (Borner et al., 1998; Brandsch 
et al., 1999). 
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 Peptide bonds: The peptide bond within a peptide structure has proved to be not 
essential requirement for the substrate of PEPT1. Enjoh demonstrated that arphamenine 
A (the peptide bond was replaced by ketomethylene bond) was transported by PEPT1 in 
Caco-2 cell with Km equaled 0.14 mM (Enjoh et al., 1996). -aminolevulinic acid (5-
ALA also bearing a ketomethylene group has been shown to be transported by PEPT1 
(Doring et al., 1998a). A more systemic investigation was then performed by Doring, and 
surprisingly found that -amino fatty acids were substrates for PEPT1. Therefore, they 
suggested that the distance between N- and C- terminal groups was more important than 
the presence of peptide bond. The optimal distance was suggested to be 5.0 to 6.35 Å 
(Doring et al., 1998b).      
 Configuration isomerism: When a peptide bond was present in di/tripeptides, 
there was trans- or cis- configuration. The configuration was critical for PEPT1 substrate. 
Brandsch demonstrated that with lower cis/trans ratio, compound Ala-[CS-N]-Pro 
exhibited significantly higher affinity to PEPT1 (Ki = 0.3 mM for lower cis/trans ratio; 
Ki = 0.51 mM for higher cis/trans ratio) (Brandsch et al., 1998). More Xaa-Pro 
dipeptides were used and confirmed that PEPT1 selectively transport only trans- 
configuration peptide (Brandsch et al., 1999).   
 Charge: The influence of charge on dipeptide affinity and transport has been 
noticed soon after PEPT1 was cloned. The general understanding was that charged 
dipeptides have lower affinity as compared to structurally similar dipeptides (Brandsch et 
al., 1999; Terada et al., 2000b). More systemic investigation regarding charge was not 
performed until 2006, Vig used a high-throughput screening method to study several 
dipeptides of PEPT1 (Vig et al., 2006). The conclusion they made was dipeptides with 
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acidic residues (negative charged) at both positions were poor substrates of PEPT1. 
However, dipeptides with basic amino acids (positive charged) at both positions were not 
substrates at all (e.g. Arg-Arg, Arg-Lys, Lys-Lys, Lys-Arg, and Orn-Orn). The rank of 
affinity of dipeptide to PEPT1 was suggested as follows: neutral-neutral > charged-
neutral ~ neutral-charged > acidic-acidic > basic-basic. This was the first data showing 
that not all of the 400 dipeptides were substrate of PEPT1 (Vig et al., 2006).  
 
Substrate Template for PEPT1 
By analysis over 100 substrates, Bailey proposed the first qualitative template for 
PEPT1 (Bailey et al., 2000). There were 10 features to consider for substrate of PEPT1. 
Four of them were thought to be the key features, which were: 1) a strong binding site for 
the N-terminal NH3
+
 group; 2) a hydrogen bond to the carbonyl group of the first peptide 
bond; 3) a carboxylate binding site which controls the preferred stereochemistry of the 
adjacent chiral contre and 4) a hydrophobic pocket with a strong directional vector 
(Figure 2.1). Few years later, Bailey further proposed a semi-quantitative method to 
predict the substrate affinity for PEPT1(Bailey et al., 2006). The brief procedures are  
     1) to assign the score of each factor that contributes to the binding;  
     2) to determine the total binding parameter T, which is the sum of 10 scores at step 1;  
     3) to multiply by 2.8 (scaling factor) to convert into binding energies G (kJ/mol);  
     4) to find the corresponding Log K by using the linear correlation plot.  
Surprisingly, the simple semi-quantitative method worked pretty well. It successfully 
made prediction of the substrate affinity for PEPT1 (Bailey et al., 2006). More details 
were listed in Figure 2.1. 
 19 
 
Quantitative Structure Activity Relationship 
 Computer simulated 3D-QSAR models for dipeptide and tripeptide were 
developed using DISCO module for the pharmacophore construction and following by 
CoMFA or CoMSIA analysis (Gebauer et al., 2003; Biegel et al., 2005). The Q-SAR 
models not only successfully predicted additional substrates, but also provided more 
detailed explanation about the substrate requirements for PEPT1. For example, the 
reduced affinity of introducing D-configured amino acid was attributed to the disfavored 
steric hindrance. The reason why modification of C- terminal groups generally more 
tolerated than modification of N- terminal groups was rationalized by the fact that at C- 
terminus the electron density was more important than the specific negative charge end. 
The design of new PEPT1 targeting drug became more visualized and logical with the 
help of 3D-QSAR models although it might need considerable computational time and 
manual optimization (Foley et al., 2010).     
 
The Mode of Transport 
 It was well accepted now that the driving forces of PEPT1 transporter are proton 
electrochemical gradient and membrane potential (Fei et al., 1994). From pre-steady state 
current analysis, a model has been proposed regarding to the transport cycle of PEPT1. 
The transport cycle was in an ordered, simultaneous transport model, in which H
+
 bound 
first to the transporter in outward facing conformation, following by a change in 
substrate-binding affinity. After the accommodating the substrate, PEPT1 underwent a 
conformational change to start the translocation process (Mackenzie et al., 1996). Similar 
model with an extension focusing on the intracellular event was supported by Nussberger, 
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suggesting a symmetry H
+
 binding intra- and extracellular model (Nussberger et al., 
1997). Since the transport via PEPT1 involved at least two binding steps, H
+
 and 
substrate, a model focusing on the substrate binding event has been further proposed. The 
substrate binding affinity of PEPT1 in outward facing conformation was 5 fold higher 
than that of inward facing conformation, which implied that the substrate binding domain 
favored the intracellular releasing of substrate rather than binding of substrate. Also, at 
saturating substrate concentration, the direction and rate of transport were determined 
solely by the membrane potential (Kottra et al., 2001).     
 Due to the fact that PEPT1 could transport charged peptide and an observation of 
increasing rate of transport at lower external pH for anionic substrate (Wenzel et al., 
1996). A different stoichiometry of proton to substrate when transporting different 
charged substrate was hypothesized and studied. Steel reported the stoichiometry of 
neutral, cationic, and anionic dipeptides as 1:1, 1:1, and 2:1 (proton : substrate) (Steel et 
al., 1997). The addition proton for anionic peptides was thought to neutralize the charge 
on the dipeptide substrate to generate a net neutral species (zwitterions). By contrast, the 
histidyl residue of PEPT1 was thought to be deprotonated to accommodate the positively 
charged moiety on cationic dipeptide. Although the stoichiometry was correct for the 
transport of different charged dipeptides, latter study showed that for cationic dipeptide, 
the position of charged residue mattered. For example, Lys-Gly, the transport occurred on 
both positively charged and neutral form, which resulted in an extra inward current. 
However, for Gly-Lys, the transport was predominantly via its neutral form rather than 
positively charged form. For anionic dipeptides, the transport with an additional H
+
 was 
to neutralize the side chain carboxyl group, which in agreement with the previous finding 
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(Kottra et al., 2002). However, limited information of charged tripeptides was available 
so far. 
 The acidic microclimate has been shown to exist and be able to provide a proton 
gradient across the intestinal epithelium (pH 6.65, jejunum v.s. pH 7.3, intracellular) 
(Daniel et al., 1989). Because the substrate transport via PEPT1 would result in the 
acidification of intracellular pH, a system to counterbalance the intracellular 
accumulation of H
+
 was needed (Fei et al., 1994). Thwaites has demonstrated that after 
adding Gly-Sar, the activity of Na
+
/H
+
 exchanger (NHE3) on the apical membrane 
increased, but remained the same on basolateral membrane (NHE1) in Caco-2 cell 
(Thwaites et al., 1999). PEPT1 activity has been shown to be influenced when inhibiting 
the NHE3 activity as well (Kennedy et al., 2002; Watanabe et al., 2005). Although the 
NHE3-coupling peptide transport pathway has been well accepted (Figure 2.2), the 
possibility that other systems involved in the maintenance of pH gradient could not 
completely rule out. NHE2, an isoform of Na
+
/H
+
 exchanger has been found to express 
on the apical membrane of duodenum and ileum in human but the contribution to PEPT1 
transporter has not been studied yet (Hoogerwerf et al., 1996). 
 
Polymorphism             
 Although only few genetic polymorphism studies have been performed, the 
overall conclusion was that PEPT1 as a conserved gene showed very low allelic 
frequencies of single-nucleotide polymorphisms (SNPs) (Zhang et al., 2004b; Anderle et 
al., 2006; Sala-Rabanal et al., 2006). In Zhang’s study, 44 ethnically diverse individuals 
were taken for SNP identification. Total 13 SNPs were identified and 9 out of them were 
nonsynonymous mutations. Using HeLa cells transfected system, 9 mutated hPEPT1were 
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expressed. Although there were overall 1.6 to 2.2 fold increase in mRNA expression, 
only P586L (1758C>T) variant (frequency = 1.1%) showed decrease of uptake of Gly-
Sar. Interestingly, the substrate specificity and substrate affinity were not affected in 
P586L variant. Instead, the immunoblot and immunocytochemistry results showed the 
reduction of protein expression of P586L. Therefore, taken together, P586L was thought 
to have profound effect on protein stability or protein translation (Zhang et al., 2004b). 
Another larger study (247 individuals) was performed across different races by Anderle. 
9 out of 17 were nonsynonymous mutations and 8 of them were further tested in Cos7 
and CHO cells transfected systems. Only one variant F28Y showed decrease affinity to 
Gly-Sar but no alteration in the protein expression and capacity. One interesting finding 
was although the allelic frequencies of many SNPs were relatively low, some SNPs 
showed ethnic bias. For example, V21I, F28Y, S117R, V112M, P537S were bias to 
African American.  
Since most allelic frequencies of SNPs of PEPT1 were relatively low, Sala-
Rabanal investigated the significance of the most frequent SNPs, S117N and G419A of 
PEPT1. Not surprisingly, S117N and G419A showed no change of capacity, affinity, and 
substrate specificity, suggesting the polymorphism of PEPT1 has low impact of oral 
peptidomimetic drugs. A pharmacokinetic study was performed to investigate the impact 
of PEPT1 on the intra- and inter-individual variabilities of valacyclovir systemic 
exposure. The result again supported that PEPT1 was a highly conserved gene, since no 
obvious contribution from SNPs was observed. The intra-individual variability was 
significant lower than inter-individual variability and even when concomitant 
administering cephalexin, the systemic exposure (AUC0→∞) was changed less than 2 fold 
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inter-individually (Phan et al., 2003). Taken all together, PEPT1 is a conserved gene with 
very stable activity in vivo, which ensures PEPT1 as a good drug delivery target.  
 
Regulation of PEPT1 
 Because PEPT1 has indispensable role in protein assimilation, the transport 
activity must be modulated to meet physiological needs. PEPT1 has been shown to be 
regulated under a variety of factors and conditions (Adibi, 2003). Although the pathways 
involved in the regulation of PEPT1 has not been fully understood, the general 
mechanisms might be categorized to: 
(1) Modification of PEPT1 protein post-translationally: Study performed in Caco-2 
cell has demonstrated that phorbol esters (PMA), an activator of protein kinase C, 
could decrease the maximal capacity (Vmax) without changing affinity (Km) of Gly-
Sar uptake (Brandsch et al., 1994).      
(2) Recruitment of PEPT1 protein from the intracellular vesicles to plasma membrane 
(cellular trafficking): Regulation has been observed when insulin was added to the 
Caco-2 cells. Specifically, Gly-Gln uptake was significantly increased with a 
change in Vmax but not Km. The increasing uptake was a result of the increasing 
amount of PEPT1 protein at the apical membrane without increasing the mRNA 
level. Since the increase could be inhibited by colchicine, a depolymerizer of 
microtubules, the regulation mechanism of insulin was suggested to increase 
translocation of PEPT1 from a preformed cytoplasmic pool (Thamotharan et al., 
1999b).  
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(3) Modification of the gene expression transcriptionally or change on mRNA stability: 
PEPT1 substrates (e.g. Gly-Sar or Gly-Gln) but not the single amino acid residues 
(e.g. Glycine, sarcosine, or glutamine) have been shown to stimulate the uptake of 
substrate in Caco-2 cells with a change of Vmax, but not Km. The increase was 
attributed to the increase of mRNA expression for PEPT1 by Northern blot analysis 
and increase of mRNA stability. (Thamotharan et al., 1998; Walker et al., 1998).  
(4) Modulation of the intracellular ion homeostasis: When one of the exchanger NHE3 
for proton balance was influenced by inhibitors, such as vasoactive intestinal 
polypeptide (VIP) or NHE3 selective inhibitor S1611, the uptake of Gly-Sar was 
significantly affected in capacity rather than affinity (Thwaites et al., 2002). 
Several factors and conditions have been demonstrated to influence the PEPT1 activity 
via one of the mechanisms above. The factors that affected PEPT1 activity could be 
generally categorized as physiological, pharmacological, and pathological. (Adibi, 2003).  
 
Physiological factors: 
A number of physiological factors have been shown to influence the PEPT1 activity. 
First, the substrate of PEPT1 has been suggested to stimulate the PEPT1 activity through 
the increase of the stability of mRNA and increase of the mRNA expression 
(Thamotharan et al., 1998; Walker et al., 1998).  
Insulin could promote the translocation of the preformed PEPT1 from the 
intracellular pool to increase the protein level of PEPT1 on membrane, which resulted in 
the increase of PEPT1 activity (Thamotharan et al., 1999b).  
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Leptin, an adipocyte secreted hormone has been shown to has short-term and long-
term effect on PEPT1 activity. Both in vitro and in vivo, leptin treated groups showed 
increase of uptake of Gly-Sar. The mechanism of increasing PEPT1 activity has been 
suggested to relate to the increase of translocation of PEPT1 from the cytoplasmic pool 
(Buyse et al., 2001) and also transcriptionally stimulated the mRNA expression via 
cAMP-response element-binding protein (CREB) and Cdx2 transcription factors to 
increase protein expression (Nduati et al., 2007). Interestingly, the leptin knockout mice 
(ob/ob) showed significant low PEPT1 protein, mRNA expression and uptake activity as 
composed to wild-type mice. However, after 7 days treatment of leptin via implanted 
mini-osmotic pump subcutaneously, the expression and activity of PEPT1 were rescued 
comparably to wild-type mice (Hindlet et al., 2007)  
Epidermal growth factor (EGF) also has agonist effect on PEPT1 activity. The 
stimulation was fairly fast since a significant increase could be measured after 5 mins 
treatment in Caco-2 cell. However, the agonist effect only took place when the EGF was 
present in the basolateral membrane side, which explained by the predominant expression 
of EGFR at basolateral membrane of Caco-2 cell (Bishop et al., 1994). The increase of 
uptake only affected the capacity (Vmax) without influenced the affinity (Km). However, 
the mechanism of the regulation was not conclusive (Nielsen et al., 2003).  
Most of hormones exhibited their effect upon binding to the corresponding receptor 
on the cell membrane (e.g. EGF – EGFR). Triiodothyronine (T3), however, initiated the 
action inside the cell, within the nucleus. Ashida showed that pretreated Caco-2 cell with 
T3 for 3 days significantly decrease the uptake of Gly-Sar. The kinetic analysis showed 
no change in affinity (Km) and decrease nearly two fold in capacity (Vmax), suggesting 
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that a decrease of the population of PEPT1 on membrane. The mechanism was suggested 
to be transcriptional, either by inhibition of transcription and/or decrease in the stability 
of mRNA. The actual bind site within nucleus has not been identified since there was no 
thyroid hormone-responsive element found upstream promoter region of PEPT1 gene 
(Ashida et al., 2002).  
Interestingly, PEPT1 also has been shown to regulate along the day (diurnal rhythm) 
and development stages. Although there was no solid conclusion being made, the general 
trend was that PEPT1 peaked at 3 pm in mRNA, protein, uptake, and capacity in 
duodenum and jejunum, where the majority of absorption occurred (Qandeel et al., 2009). 
As for the development stages, the mRNA and protein expression of PEPT1 peaked on 
day 3 to 5 after birth and transiently rose on day 24, when was about the time of weaning 
(Shen et al., 2001).    
             
Pharmacological factors:  
5-fluorouracil was an anticancer agent, which has deleterious effect on the 
intestinal mucosa layer and intestinal villus. After 3 days orally administered of 5-
fluorouracil in rat, the villus height was markedly decrease and atrophy of mucosa layer 
was noticed. Under this circumstance, the uptake activities of D-glucose and amino acid 
glycine were significantly impaired except for PEPT1 and the mRNA expression of all 
the detected enzymes and transporters were decreased except for PEPT1 (increase > 2 
fold). Therefore, it was believed the preservation of PEPT1 activity was due to the 
increase of synthesis of PEPT1, which resulted in a normal protein expression as 
compared to control (Tanaka et al., 1998).  
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Clonidine is an agonist for 2-adrenergic receptors, which has been shown to 
increase the cephalexin plasma concentration after i.v. bolus (Berlioz et al., 1999). A 
subsequent study was found that the increase of cephalexin uptake was involved in the 
increase of expression of PEPT1, the transporter for cephalexin. The change affected only 
on Vmax, not on Km and the regulatory mechanism was confirmed by clochicine 
abolishment of the stimulation, suggesting an increase of the translocation of preformed 
cytoplasmic PEPT1 (Berlioz et al., 2000).  
The regulation of a selective -ligand pentazocine was also investigated in the 
Caco-2 cells. The results revealed that PEPT1 mRNA was increased along with the 
uptake activity of Gly-Sar in a dose dependent and time dependent manners. The kinetic 
analysis showed that the stimulation of PEPT1 activity changed only in Vmax, not in Km 
(Fujita et al., 1999).  
Immuosuppressive drugs tacrolimus and cyclosporine were other examples. They 
both have been found to decrease the PEPT1 activity by changing the Vmax rather than 
Km (Motohashi et al., 2001). 
 
Pathological factors:  
PEPT1 as the major peptide transporter in the intestine has been shown to have 
obligatory role in protein assimilation (Ganapathy et al., 2006). Therefore, it appears to 
be interesting to study the effect of malnutrition on the function and expression of 
intestinal PEPT1. The effect of brief and prolonged fasting on PEPT1 has been studied. 
Thamotharan showed that the Gly-Gln uptake significantly increased after 1 day fasting 
in rat by brush-border membrane vesicle. The expression of PEPT1 was also increased in 
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both mRNA and protein levels. The kinetic analysis suggested that the Vmax was increase 
by 2 fold, whereas the Km was unaffected (Thamotharan et al., 1999a). A prolonged 
fasting (starvation) study, which rats were starved for 4 days and semistarved (50% 
amount of control) for 10 days has been performed and demonstrated an increase of 
mRNA and protein in both groups (mRNA increase 179% and 164% for starvation and 
semistarvation, respectively). In contrast to the increase mRNA expression of PEPT1, the 
mRNA of sodium-dependent glucose transporter 1 (SLGT1) had no significant change 
(Ihara et al., 2000). Additional study visualized the PEPT1 upregulation by 
immunofluorescence localization technique and suggested the increasing PEPT1 protein 
was mainly at the tip of villus as opposed to the crypt (Ogihara et al., 1999). Therefore, it 
has been suggested the upregulation of PEPT1 under starvation condition was possibly an 
adaptive response to absorb every possible nutrient in the lumen (Ogihara et al., 1999). 
Diabetes is another interesting pathological condition to study its effect on PEPT1. 
Since it has been demonstrated that insulin could increase PEPT1 activity by promoting 
the translocation of the preformed PEPT1 from the intracellular pool (Thamotharan et al., 
1999b), diabetes has been expected to have down-regulated effect on PEPT1.  
Unexpectedly, in the streptozotocin-injected diabetic animals, the uptake of Gly-Gln was 
increased with a change in Vmax rather than Km. The mechanism of increasing PEPT1 
activity in this insulin deprived diabetic rat was found to be the increase of mRNA 
stability since the transcriptional rate showed no difference (Gangopadhyay et al., 2002).   
Proinflammatory cytokines could be induced under bacteria or parasite infection. 
Studies have suggested that PEPT1 was upregulated under infection condition. 
Cryptosporidium Parvum induced diarrhea was commonly seen in humans. Study has 
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shown that PEPT1 mRNA was increased on day 10, when was the peak of infection in 
the distal small intestine in the suckling rats model. After the spontaneous clearance of 
the parasite, PEPT1 mRNA returned to normal (Barbot et al., 2003). Although atrophy 
was normally present in the infection condition, which was a factor (malnutrition) that 
stimulated PEPT1 expression (Thamotharan et al., 1999a), the increase of cytokine IFN- 
was believed to be the actual factor responsible for the upregulation (Marquet et al., 
2007).    
 
Involvement of PEPT1 in Inflammatory Bowel Disease  
 It has been shown that PEPT1 normally expressed in small intestine, not in colon 
(Ogihara et al., 1996). However, in an extreme condition, humans with short-bowel 
syndrome (SBS), PEPT1 has been shown to upregulate in the colon epithelium (Ziegler et 
al., 2002). Merlin first hypothesized the possibility that aberrant colonic PEPT1 might 
interact with the bacterial peptides in colon. Caco-2 cell served as a best model for this 
purpose because Caco-2, a colon cancer cell, did express PEPT1 transporter. The 
bacterial peptide, N-formyl-Met-Leu-Phe (fMet-Leu-Phe) has been shown to be actively 
transported into Caco-2 cell via PEPT1. Most interestingly, fMet-Leu-Phe could promote 
the neutrophil transmembrane migration and the migration could be reduced by PEPT1 
substrate Gly-Pro and Gly-Leu, but not glycine, suggesting that PEPT1 transporter was 
involved in the neutrophil transmembrane migration (Merlin et al., 1998). In a 
subsequent study, the aberrant colonic PEPT1 expression in the colon epithelium of 
inflammatory bowel disease (IBD) patient (both CD and UC) has been demonstrated. By 
transfecting HT29-Cl.19A, a cell line does not express PEPT1 with a hPEPT1 construct, 
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the uptake of Gly-Sar increased and the uptake of fMet-Leu-Phe resulted in an increase 
the MHC class I expression, suggesting the functional consequence of the aberrant 
colonic expression of PEPT1 in the patient with IBD (Merlin et al., 2001). In addition to 
in vitro system, an in situ perfusion system has demonstrated an increase of 
myeloperoxidase (MPO) activity after perfusion of fMet-Leu-Phe in jejunum, but not in 
colon, suggesting that the uptake of fMet-Leu-Phe (kinetic) could translate into the 
increase of MPO activity (dynamic) because by adding Gly-Gly, the increase of MPO 
activity would reversed to control level (Buyse et al., 2002). After the hypothesis of the 
involvement of PEPT1 in intestinal inflammation and/or IBD, more studies focusing on 
the impact of proinflammatory cytokine on PEPT1 activity. Interferon- has been 
demonstrated to increase Gly-Sar uptake in a dose and time dependent manners in Caco-2 
BBE cell. The uptake fMet-Leu-Phe, a bacterial peptide also has been shown to increase 
in the presence of interferon-The stimulation of Gly-Sar uptake by interferon- was 
specific to PEPT1 since in another cell line HT29-Cl.19A, the stimulation was not 
observed. The mechanism of the stimulation of PEPT1 activity by interferon- was found 
to be the increase of intracellular pH upon application of interferon-. The protein and 
mRNA expression of PEPT1 did not change in the presence of interferon- (Buyse et al., 
2003). Similar effect of interferon- on Gly-Sar uptake was also observed in another 
study. However, in this study, after application of interferon-, an increase of mRNA and 
protein level of PEPT1 has been demonstrated (Foster et al., 2009).  
Muramyl dipeptide (MDP), a ligand of NOD2 receptor has been shown to be the 
substrate of PEPT1 as well (Ogura et al., 2001). MDP has been demonstrated to exhibit 
an inhibitory effect on Gly-Sar uptake in a stereospecificity manner and could be 
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transported directly with Km around 4.3 mM in Caco-2 BBE cells. More importantly, the 
transport of MDP caused an increase release of IL-8 and MCP-1 and activation of NF-B. 
Application of siRNA of PEPT1 and NOD2 reduced the increasing release of IL-8 in the 
presence of MDP in the Caco-2 BBE cells (Vavricka et al., 2004). Another bacterial 
peptide L-Ala--D-Glu-meso-DAP (Tri-DAP) has also been suggested to be the substrate 
of PEPT1 recently (Dalmasso et al., 2010).   
The regulation of PEPT1 by proinflammatory cytokines has also been shown in 
vivo. Mice intraperitoneally injected TNF- and IFN- have been demonstrated to 
upregulate the protein expression and the transport activity of PEPT1 (Gly-Sar uptake) in 
the proximal and distal colon, but no change of mRNA of PEPT1 has been observed, 
which provided supportive data for the hypothesis that PEPT1 was involved in the 
intestinal inflammation and/or IBD (Vavricka et al., 2006). Therefore, a hypothesized 
model for the involvement of the aberrant colonic hPEPT1 in IBD has been proposed 
(Figure 2.3) (Charrier et al., 2006b).  
Soon after the model has been proposed, more studies using experimental colitis 
animal models to elucidate the role of colonic PEPT1 have been performed. Dextran 
sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) induced colitis animal 
models were used to investigate the role of colonic PEPT1. Dalmasso showed that a 
bioactive tripeptide Lys-Pro-Val (KPV) could ameliorate the colitis in two animal models. 
Because Lys-Pro-Val (KPV) has been also shown to be the substrate of PEPT1 in the 
study and previously study demonstrated the upregulation of PEPT1 in colon under 
inflammation condition in rat after DSS treatment by immunohistochemistry (IHC) 
(Radeva et al., 2007), Dalmasso suggested that the effect of Lys-Pro-Val (KPV) was 
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partly due to the increase of activity of PEPT1 in colon (Dalmasso et al., 2008). Another 
intriguing colitis model has been used to investigate the role of PEPT1 in colon. In the 
study, an upregulation of PEPT1 has been demonstrated in the presence of pathogenic 
bacteria enteropathogenic Escherichia coli (EPEC) in HT29-Cl.19A cells in vitro and in 
the presence of Citrobacter rodentium in vivo (Nguyen et al., 2009). Unexpectedly, the 
severity of infection by Citrobacter rodentium for hPEPT1 transgenic mice was lesser 
than that of wild-type mice regarding to the expression of pro-inflammatory cytokines, 
chemokines, and anti-inflammatory cytokines (i.e. IL-1, IL-6, IL-12p35, IL-12p40, 
TNF-, IFN-, IL-10, and TGF-). One explanation was that PEPT1 could attenuate the 
bacteria adherence to the lipid raft, which has been shown in the EPEC adherence study 
in hPEPT1 transfected HT29-Cl.19A cell. Although it seemed to conflict the hypothesis 
being proposed earlier, an interesting finding from a genetic polymorphism associated 
with inflammatory bowel disease study supported the contradiction (Zucchelli et al., 
2009). The common variant of PEPT1 (Ser117Asn) was found to associate with 
inflammatory bowel disease in two populations (Sweden and Finland) with opposite 
genetic effect (risk and protection, respectively), indicating the complexity of the role of 
PEPT1 in inflammatory bowel disease.   
The results from the study investigating the role of colonic PEPT1 seemed to be 
disease model dependent. Unlike previous results in Citrobacter rodentium infection 
model, the colitis severity was higher in two types of hPEPT1 transgenic mice models 
than that of wild-type mice. However, not only the colitis induction method, but also the 
type of transgenic mice used affected the overall outcome. In the study, TNBS induced 
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colitis model failed to exhibit difference between villin-directed hPEPT1 transgenic mice 
and wild-type mice (Dalmasso et al., 2011a).    
Several other colitis induction models have suggested the important role of 
aberrant expression of colonic PEPT1. Intestine resection rat model has been shown to 
upregulate PEPT1 in the colon at week 2 (Shi et al., 2006a; Shi et al., 2006b). The 
functional consequence of the upregulation of colonic PEPT1 has been shown by 
perfusing the bacterial tripeptide fMet-Leu-Phe. The MPO activity was increased after 
perfusion of fMet-Leu-Phe in the resection rats but not in the transection rats. IL-10 
knockout mice model has been shown to upregulate PEPT1 in colon as well (Chen et al., 
2010). The mRNA and protein expression level of PEPT1 were increased in the IL-10 
knockout mice as compared to wild-type mice. Also, the uptake of cephalexin, a PEPT1 
substrate from colonic perfusion was increase in the IL-10 knockout mice as compared to 
wild-type mice. One of the therapeutic alternatives, Lactobacillus plantarum (LP) was 
also investigated in this study. It demonstrated a reduction of pro-inflammatory cytokines 
TNF- and IFN- along with the decrease expression of colonic PEPT1 in mRNA and 
protein and decrease of the uptake of cephalexin from colon. The results suggested that 
the decrease of inflammatory response by LP treatment might associate with the decrease 
of colonic PEPT1 since PEPT1 has been shown to transport many bacterial peptides 
(Merlin et al., 1998; Vavricka et al., 2004; Dalmasso et al., 2010).       
A novel post-transcriptional regulation of PEPT1 by MicroRNA-92b has been 
demonstrated in Caco-2 BBE cells (Dalmasso et al., 2011b). The regulation might also be 
related to intestinal inflammation since the L-Ala--D-Glu-meso-DAP (Tri-DAP) 
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induced proinflammatory responses could be ameliorated in the presence of MicroRNA-
92b in Caco-2 BBE cells.  
A table of studies focusing on PEPT1 related to intestinal inflammation was listed 
on Table 2.1.   
 
INFLAMMATORY BOWEL DISEASE 
Description 
 Inflammatory bowel disease (IBD) is characterized in two phenotypes, Crohn’s 
disease (CD) and ulcerative colitis (UC). The distinction between two types of IBD is the 
clinical presentation (e.g. location of inflammation, type of inflammation). CD causes 
transmural inflammation and affects any part of the gastrointestinal tract, typified by the 
formation of granulomas, stricturing and fistulae histologically. In contrast, UC is limited 
to the colon and typified by mucosal inflammation (Abraham et al., 2009).  
Incidence and Prevalence 
 The prevalence of IBD (CD and UC) in the U.K. are 214 per 100,000 and 122 per 
100,000, respectively. However, there are significant variations across the regions 
(Shivananda et al., 1996). In the United States, it affects approximately 1.4 million 
Americans and its peak onset is at age 15 to 30 years (Loftus, 2004).  
Aetiology 
 Although IBD has been known for over 50 years, the exact causes and 
mechanisms have remained unclear because of the different presentations of disease and 
the involvement of multifactorial background of disease patterns (Corfield et al., 2011). 
Despite the uncertainties of the pathogenesis of IBD, there have been several factors 
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proposed to confer to the susceptibility of IBD, which were genetics (including immune 
response and epithelial barrier function), immune dysregulation, and environmental 
factors (e.g. microbial flora, smoking, diet, drug) (Kucharzik et al., 2006; Xavier et al., 
2007).   
Genetics:  
There have > 100 susceptible genes for CD, > 50 genes for UC, and ~ 50 genes 
shared between them (Corfield et al., 2011) been identified. They could generally be 
classified as: 
(1) Innate immune response linked: NOD2 (nucleotide-binding oligomerization 
domain 2), TLR4 (Toll-like receptor 4) and NALP3 [NLR (NOD-like receptor) 
family, pyrin domain-containing 3]. 
(2) Autophagy linked: NOD2, ATG16L1 (autophagy-related 16-like 1), IRGM 
(immunity-related GTPase) and DAP (death-associated protein). 
(3)  Epithelial barrier function linked: GNA12 (guanine-nucleotide-binding protein 
α12), HNF4 (hepatocyte nuclear factor 4), CDH1 (cadherin 1), LAMB1 (laminin 
β1), MDR1, and MUC2. 
(4) Adaptive immune response linked: HLA class 2, IL10 (IL is interleukin), IL12, 
IL17, IL23, and IL23R (IL-23 receptor) related to T-cell function. 
NOD2 is an intracellular pattern-recongnition receptor (PRR), which recognizes 
the common breakdown product of peptidoglycan cell wall, muramyl dipeptide (MDP), 
followed by activating innate immune system via NF-B and MAPK pathway (Kelsall, 
2005). Genomic analysis of patients with CD revealed that people with NOD2 mutations 
were more susceptible to CD (Hugot et al., 2001; Ogura et al., 2001). In vitro data 
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showed that peripheral blood mononuclear cells (PBMCs) from CD patients with NOD2 
frameshift mutation no longer respond to NOD2-activating agonists (Netea et al., 2005). 
However, this loss of function phenomenon was conflicted with data from a mouse model 
with NOD2 framshift mutation similar to human homologous, which showed an increase 
cytokine secretion when challenging with dextran sodium sulfate (DSS) (Maeda et al., 
2005). One explanation for the deficiency of in vitro and in vivo was proposed by using 
NOD2 knockout mice. The data have shown that the loss of NOD2 resulted in the 
decrease of cryptdins (-defensin in human) expression produced in intestinal Paneth 
cells. Therefore, the control over the intestinal bacteria was impaired (Kobayashi et al., 
2005). Another explanation was that NOD2 was a negative regulator of TLR2 signaling 
pathway and the dysfunction of NOD2 enhanced the Th1-mediated inflammatory 
response (Watanabe et al., 2004). It has been further supported from the data of NOD2 
transgenic mice model, which resulted in the increase production of IL-12 and the 
susceptibility were decrease by challenging with peptidoglycan and trinitrobenzene 
sulfonic acid (TNBS) as compared to wild-type mice (Yang et al., 2007).  
Another gene related to the epithelial barrier of intestine MUC2, which encoded 
the mucin protein has been demonstrated to be a key gene for IBD as well. In a MUC2 
knockout mice study, deletion of MUC2 resulted in the spontaneously development of 
colitis. When challenging with DSS, the MUC2 knockout mice exhibited earlier onset 
and higher disease activity index as compared to wild-type mice (Van der Sluis et al., 
2006).  
Immune Dysregulation: 
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 The mucosal homeostasis is a balancing act between effector cells and regulatory 
cells. Either excessive effector cells or shortage of regulatory cells would end up with a 
dysregulation of mucosal homeostasis (Kucharzik et al., 2006). Both types of 
dysregulation have been demonstrated in the literature. IL-12 (Monteleone et al., 1997), 
TNF- (Breese et al., 1994), and IFN- (Fuss et al., 1996) have been shown to 
overproduce in CD patients. In addition, study has shown that the number of regulatory T 
cells decreased in the peripheral blood in active IBD patients (Maul et al., 2005). The 
hypothesis of immune dysregulation has been further proven by the development of 
several colitis mice models. One example was TNF
ARE
 mutant mice, by increasing the 
mRNA stability of TNF- resulting in the overproduction of TNF-. These mice 
developed CD-like phenotype in the terminal ileum or proximal colon at age of 2 to 4 
weeks. The other type of model was due to the impaired regulatory cell response, such as 
IL-10 deficient mouse (Kuhn et al., 1993) and TGF- deficient mice (Shull et al., 1992). 
These mice developed colitis spontaneously at around age of 4 weeks. Taken together, 
from the clinical observation and experimental mice models, the importance of the 
balance of effector and regulatory cells to the IBD have been delineated.      
Environmental Factors: 
 The clinical association between microbiome and IBD has been observed 
(Swidsinski et al., 2002). However, the role of human gut microbiome in the IBD has 
been focused recently due to the better understanding and analytic methods of human 
microbial flora (Flanagan et al., 2011). Both commensal organism and pathogenic 
organism have been shown to associate with IBD. Faecalibacterium prauznitzii, a 
member of the C. leptum group was found to be negatively associated with the ileal CD. 
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Individual with predominantly ileal CD had lower abundance of Faecalibacterium 
prauznitzii, but increasing abundance of Escherichia coli as compared to healthy subjects 
(Willing et al., 2009). Interestingly, oral administration of either live or the supernatant of 
Faecalibacterium prauznitzii showed a reduction of the severity of TNBS induced colitis 
in mice (Sokol et al., 2008). On the other hand, the pathogenic bacteria, such as 
Mycobacterium avium subsp. Paratuberculosis (MAP) has been postulated as a potential 
pathogenic agent in CD due to the finding of MAP’s DNA within the granulomas of CD 
patients (Ryan et al., 2002). 
Conventional Medical Management of Inflammatory Bowel Disease 
 Since there is no known cure for IBD, the principles of therapy for IBD are first, 
to induce remission and to maintain remission over time. Second, to heal the inflamed 
mucosa, maintain the quality of life, improve nutritional status, and prevent 
complications (Katz, 2007). With the advancement of medicines and the experience and 
knowledge of IBD, the therapeutic strategy evolved over time in terms of the 
optimization of drug type, timing, and context (Burger et al., 2011). Current options for 
IBD included 5-aminosalicylates (5-ASAs; sulphasalazine, mesalazine, olsalazine, 
balsalazide), corticosteroids (prednisolone, prednisone, 6-methylprednisolone, and 
budesonide), immunosuppressive agents (6-mercaptopurine (6-MP), azathiprine  
methotrexate), and anti-tumor necrosis factor agents (infliximab, adalimumab, 
certolizumab). In more serve situation, surgery will be another option.  
Future Therapeutic Options for Inflammatory Bowel Diseases 
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 With increasing knowledge in immunology and the mechanism of inflammatory 
bowel disease, development of new class of therapeutic alternatives has evolved 
dramatically. Some new class therapeutic agents were listed below (Plevy et al., 2011):  
(1) Targets in mucosal immunity: anti-IL-12/23 mAb, anti-IL-23 mAb, anti-IL-17, IL-
6 inhibitors, other TNF inhibitors, anti-a4b7 mAb, anti-a7 mAb, anti-MADCAM 
mAb,  CCR9 antagonist. 
(2) Targeting therapies to sites of inflammation: delivery of KPV and siRNAs.  
(3) Cell-based therapeutics: Stem cell, autologous bone marrow transplant. 
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Figure 2.1. Structure template for PEPT1 (Adopted from Bailey et al., 2006). 
 
 
 
 
 
 
 
 
# Factor description
1 An N-termial -NH3+ group 1o amines +2
2o and/or aryl amines 0
Others -2
2 Stereochemistry at C of R
1 Ttemplate stereochemistry at -C1 +1
Planar 0
Incorrect stereochemistry -1
3 Planar backbone from N-terminal Ca to R
2
Planar from -C1 → side-chain of 2nd residue +1
4 A hydrogen bond to the first peptide C=O Any C=X (where X is heteroatom with lone pair) at the 1st peptide bond +1
5 No alkylation of N2-amide NH Alkylation of N2-amide nitrogen -1
6 Stereochemistry at Ca of R2 Ttemplate stereochemistry at -C1 +2
Planar 0
Incorrect stereochemistry -2
7 Hydrophobic pocket for R2, possessing a strong directional vector as indicated (+2 per aryl group) Each aryl ring in pocket +2
Each charge in pocket -1
8 A carboxylate binding site Carboxylate within H-bonding distance of histidine in template +2
9a For larger substraes: space for side-chain R3 Template stereochemistry at -C3 0
Planar -1
Incorrect stereochemistry -2
9b An alternative (tripeptide) carboxylate binding site Carboxylate within H-bonding distance of histidine in template +2
10 Size Mr < 300 -1
Mr > 300 -2
score
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Figure 2.2. Pathway of peptide absorption (Adopted from Daniel et al., 2004). 
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Figure 2.3. Model of the involvement of hPEPT1 in IBD (Adopted from Charrier 
et al., 2006). 
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Table 2.1. List of studies focusing on PEPT1 related to intestinal inflammation. 
 
Model Result Reference
Caco-2 BBE / neutrophil * fMet-Leu-Phe was transported by PEPT1
* fMet-Leu-Phe induced neutrophil transmigration
(Merlin et al., 1998)
Oocyte * fMet-Leu-Phe was transported by PEPT1
* Gly-Sar upatke was inhibited by fMet-Leu-Phe
(Merlin et al., 1998)
Colon of UC and CD patients * Aberrant colonic PEPT1 expression in the colon of CD and UC patient
 (Merlin et al., 2001) 
HT29-Cl.19A / GFP-hPepT1 * Uptake of fMet-Leu-Phe increased MHC class I expression (Merlin et al., 2001) 
Rat perfusion * fMLP perfusion increase the MPO activity in jejunum, but not in colon
* Gly-Gly successfully inhibited the increased MPO activity in jejunum
(Buyse et al., 2002)
Caco-2 BBE * fMet-Leu-Phe uptake stimulate NK-B and AP-1 (Buyse et al., 2002)
Caco-2 BBE * IFN- increased Gly-Sar and fMet-Leu-Phe uptake 
* IFN- increased the intracelluar pH rather than mRNA or protein expression level of PEPT1 
(Buyse et al., 2003)
Caco-2 * IFN- increased Gly-Sar permeability
* IFN- increased the mRNA and protein expression level
(Foster et al., 2009)
Caco-2 BBE * MDP was transported by PEPT1 (Km = 4.3 mM)
* Stereoisomers of MDP (LL, DD) were not PEPT1 substrates
* MDP induced IL-8, MCP-1, and NF-kB
(Vavricka et al., 2004)
Caco-2 BBE * TNF- and IFN- increased the Gly-Sar uptake (Vavricka et al., 2006)
Mouse * TNF- and IFN- increased the protein level of PEPT1 and Gly-Sar uptake 
* TNF- and IFN- did not affect mRNA level of PEPT1
(Vavricka et al., 2006)
human * PEPT1 upregulated in colon of IBD patient
* Current model of PEPT1 involved in the IBD
(Charrier et al., 2006b)
Rat / DSS * PEPT1 upregulation was observed by IHC in distal colon
* mRNA decrease in most of intestinal segments except for distal colon
* no protein level of PEPT1 changed was observed by western blot 
* Pharmacokinetic profiles of cephalexin and valacyclovir showed no difference
(Radeva et al., 2007)
Mouse / DSS and TNBS * KPV ameliorate the inflammation induced by DSS and TNBS (Dalmasso et al., 2008)
HT29-Cl.19A / EPEC * Enteropathogenic Escherichia coli (EPEC) upregulated PEPT1 expression (Nguyen et al., 2009)
Mouse / Citrobacter rodentium * PEPT1 upregulation after Citrobacter rodentium infection in proximal and distal colon
* Severity of Citrobacter rodentium infection in hPEPT1 transgenic mice was lesser than wild type mice 
regarding to cytokines mRNA expression
(Nguyen et al., 2009)
Human * Genetic polymorphism study revealed an oppsite genetic effct on PEPT1 associated with IBD (Zucchelli et al., 2009)
Caco-2 BBE * L-Ala-gamma-d-Glu-meso-DAP (Tri-DAP) decreased the Gly-Sar uptake (Dalmasso et al., 2010)
Mouse * L-Ala-gamma-d-Glu-meso-DAP (Tri-DAP) increased KC release in hPEPT1 transgenic mice (Dalmasso et al., 2010)
Mouse / DSS and TNBS * DSS treated mice showed higher severity in both -actin and villin-directed transgenic mice
* TNBS treated mice only showed higher severity in -actin directed transgenic mice
* hPEPT1 transgenic / NOD2-/- suggested the inflammatory activity of hPepT1 is NOD2-dependent
(Dalmasso et al., 2011)
Caco-2 BBE * MicroRNA-92b down-regulated PEPT1 and ameliorated the Tri-DAP induced inflammatory response (Dalmasso et al., 2011b)
Mouse / Lactobacillus plantarum (LP) * IL-10 knockout mice increased the mRNA and protein expression of PEPT1 in colon
* Functional activity of PEPT1 also increased in IL-10 knockout mice in cephalexin colonic perfusion
* LP ameliorated the inflammatory response (TNF-, IFN-) and decreased the mRNA and protein 
expression of colonic PEPT1
(Chen et al., 2010)
Rabbit /  Eimeria magna oocytes * chronic inflammation induced by  Eimeria magna oocytes decrease the Km of Gly-Sar rather than V max
* no change of PEPT1 mRNA was observed
(Sundaram U et al., 2005)
Rat / LPS * no PEPT1 regulation was observed after 24 h LPS treatment (Mori N et al., 2011)
Rat / DSS * Decrese of PEPT1 mRNA was observed in jejunum and ileum (Shu HJ et al., 2002)
Suckling rat / Cryptosporidium parvum * PEPT1 mRNA increase was observed (Barbot et al., 2003)
Suckling rat / Cryptosporidium parvum * PEPT1 protein showed no change (Marquet et al., 2007)
Xenopus laevis  oocyte * MDP and fMet-Leu-Phe were transported by hPEPT1
* NOD1 activating muramyl peptides were not hPEPT1 substrates
(Ismair MG et al., 2006)
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Chapter 3 
 
IMPACT OF INTESTINAL PEPT1 ON THE KINETICS AND DYNAMICS OF N-
FORMYL-METHIONYL-LEUCYL-PHENYLALANINE (FMET-LEU-PHE), A 
BACTERIALLY-PRODUCED CHEMOTACTIC PEPTIDE 
 
ABSTRACT 
PEPT1 has been suggested recently to transport bacterially-produced small 
peptides, which raised the possibility that PEPT1 has a pathological role in intestinal 
inflammation. The purpose of this study was to evaluate the impact of PEPT1 on the 
kinetics and dynamics of a bacterially-produced chemotactic tripeptide N-formyl-
methionyl-leucyl-phenylalanine (fMet-Leu-Phe). Using an in situ single-pass intestinal 
perfusion technique in wild-type and Pept1 knockout mice, the intestinal transport of 
fMet-Leu-Phe was saturable and primarily due to PEPT1 (Km = 1.6 mM. The peptide-
histidine transporters, PHT1 and PHT2, were not involved in the intestinal transport of 
fMet-Leu-Phe due to a lack of inhibition by L-histidine. The permeability of fMet-Leu-
Phe was substantial and comparable in the duodenum and jejunum of wild-type mice, 
about one-half that in ileum, and very low in colon.  In contrast, the permeability of fMet-
Leu-Phe was very low in all intestinal segments of Pept1 knockout mice and showed no 
difference between these segments or that of colon in wild-type mice. 
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Myeloperoxidase activity (a measure of neutrophil migration) was significantly 
increased when perfusing fMet-Leu-Phe in the jejunum of wild-type mice and was 
abolished by adding glycylglycine, an inhibitor of PEPT1 transport; no change was 
observed in the jejunum of Pept1 knockout mice. Likewise, no increase of MPO activity 
was observed in the colon of both wild-type and Pept1 knockout mice. Difference in 
enzymatic activity between genotypes was ruled out since fMet-Leu-Phe hydrolysis in 
jejunal homogenates was not different between wild-type and Pept1 knockout mice. In 
conclusion, our data suggested that intestinalPEPT1 was responsible for the transport and 
the dynamic activity of the bacterially-produced compound fMet-Leu-Phe. 
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INTRODUCTION 
Since PEPT1, a proton-coupled oligopeptide transporter, has been cloned from the 
rabbit intestine (Fei et al., 1994), several studies have suggested that the end products of 
the digested protein were predominantly absorbed by PEPT1 in the form of di/tripeptides 
rather than free single amino acids (Ganapathy et al., 2006). PEPT1 expressed throughout 
the small intestine (duodenum, jejunum, and ileum), but with little or none expression in 
the colon (Ogihara et al., 1996). The immunofluorescent staining showed that PEPT1 
expressed mainly at the apical side of the enterocyte with decreasing expression from the 
tip to the crypt of the villus (Ogihara et al., 1996). Theoretically, PEPT1 transports 400 
dipeptides and 8,000 tripeptides, but it has been suggested that not all the di/tripetides are 
transported by PEPT1 (Vig et al., 2006). In addition to endogenous oligopeptides, PEPT1 
can transport several peptidomimetics such as -lactam antibiotics (Okano et al., 1986), 
angiotensin-converting enzyme inhibitor (Thwaites et al., 1995), the anticancer drug 
bestatin (Tomita et al., 1990), and the antiviral drug valacyclovir (Ganapathy et al., 1998). 
Due to the broad spectrum of substrate specificity, PEPT1 has been targeted as a delivery 
route to increase the bioavailability of poorly absorbed compounds recently. A successful 
example, valacyclovir has been shown to exhibit 3-5 fold increase in bioavailability as 
compared to its parent compound acyclovir (Soul-Lawton et al., 1995). 
PEPT1 regulation in various conditions have been reported recently (Adibi, 2003). 
Substrates, pharmacological agents, hormones, and diseases have been shown to modify 
the expression of PEPT1 in the mRNA or protein levels. Most interestingly, PEPT1 can 
also be regulated in the colon, where normally no PEPT1 expressed, under some 
intestinal disease conditions. For example, PEPT1 was detected at the apical membrane 
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of colon in patients with Crohn’s disease and ulcerative colitis by immunohistochemical 
staining (Merlin et al., 2001). This upregulation of PEPT1 was also observed in the colon 
of patients with short bowel syndrome (SBS) (Ziegler et al., 2002). Therefore, a 
pathological role of PEPT1 in colon related to the upregulation has recently been 
proposed (Charrier et al., 2006b), based on the ability of transporting bacterially-
produced peptides and the aberrant expression in colon. One category of bacterial peptide 
is N-formyl peptide. Study has shown that the major one produced by E. Coli. was a 
tripeptide, N-formyl-methionyl-leucyl-phenylalanine (fMet-Leu-Phe) (Marasco et al., 
1984). The endogenous concentration of fMet-Leu-Phe was around 100 nM in human 
colon (Marasco et al., 1984). PEPT1 transporter as well as its homolog, PEPT2 
transporter have been shown to transport some bacterially-derived compounds, such as 
fMet-Leu-Phe, muramyl-dipeptide (MDP), and -D-glutamyl-meso-diaminopimelic acid 
(-iE-DAP) (Merlin et al., 1998; Vavricka et al., 2004; Swaan et al., 2008). The 
functional consequence of uptaking bacterially-derived compounds has also been 
demonstrated in the cell culture systems and perfusion study (Merlin et al., 1998; Merlin 
et al., 2001; Buyse et al., 2002). The MHC class I expression and the neutrophil 
transmigration increased in CaCo-2 and cell line that expressing PEPT1 transporter and 
the increase can be moderated by specific substrate inhibition indicating a PEPT1-
mediated fMet-Leu-Phe transport was involved. In addition to the in vitro studies, one 
study performing in situ intestinal perfusion of fMet-Leu-Phe in rat jejunum also 
demonstrated an increasing myeloperoxidase (MPO) activity in the presence of PEPT1. 
The other animal model of SBS, 80% small intestine resection also showed increasing 
MPO activity when perfusing fMet-Leu-Phe in colon, which provided the possible 
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consequence of the upregulation of PEPT1 in the colon (Buyse et al., 2002; Shi et al., 
2006). Therefore, a hypothesis was proposed that colonic PEPT1 is involved in the 
intestinal inflammation in disease condition rather than just being as a nutritional 
transporter (Charrier et al., 2006b).  
Nonetheless, most of the kinetic studies were performed in the cell culture models, 
and only functional consequences were examined in those in situ studies. Direct 
measurement of the kinetic of bacterially-produced peptides transport in situ has not been 
demonstrated so far. Also, the possibility that other oligopeptide transporter involved in 
the transport of those bacterially-produced peptides still cannot be ruled out. In our 
previous studies, by using single-pass intestinal perfusion technique, a significant 
reduction of effective permeability of glycylsarcosine (Gly-Sar) has been shown in the 
Pept1 knockout mice as compared to wild-type mice, which provided a useful technique 
to examine the substrate specificity and kinetics of PEPT1 in the intestine (Jappar et al., 
2010). Therefore, in the present study the PEPT1-mediated transport of fMet-Leu-Phe (a 
bacterially-produced peptide) was evaluated using a single-pass intestinal perfusion 
technique in mice. In particular, the regional permeability, concentration dependency, 
substrate specificity, and dynamic activity of fMet-Leu-Phe were studied in wild-type and 
Pept1 knockout mice.      
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MATERIALS AND METHODS 
Materials   
[
3
H-Phe] fMet-Leu-Phe (15 Ci/mmol) was purchased from AmBios Labs 
(Newington, CT). [
14
C] Inulin (2.38 mCi/g) was purchased from Moravek Biochemicals 
and Radiochemicals (Brea, CA). Glycyl-Proline (Gly-Pro) was obtained from Bachem 
(Torrance, CA). All other chemicals were acquired from Sigma-Aldrich (St. Louis, MO). 
Animals   
Mouse experiments were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the U.S. National Institutes of Health. 
Gender-matched wild-type and Pept1 knockout mice (8-10 week old) were used in all the 
experiments. The mice were kept under a 12-hr light and 12-hr dark cycle, and fed ad 
libitum with standard diet and water (Unit for Laboratory Animal Medicine, University of 
Michigan, Ann Arbor, MI).   
Intestinal fMet-Leu-Phe Metabolism and Exposure in Portal Vein 
1 cm of each intestinal segment (duodenum, jejunum, ileum, colon) of wild-type 
mice was taken and exposed the luminal surface longitudinally. Each intestinal segment 
was incubated with 0.5 ml PBS (pH 7.4) containing 0.8 mM fMet-Leu-Phe at 37
o
C for 5 
mins. After incubation, solution was placed on ice and added 10 l 10% TFA. Analysis 
was done by HPLC with 250 x 4.6 mm C18 column (Symmetric®, Waters, Milford, MA). 
The mobile phase consisted of 100% acetonitrile plus 0.1% TFA (buffer A) and 100% 
H2O plus 0.1% TFA (buffer B). A gradient flow was used, starting from 15% buffer A to 
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30% buffer A over 30 min. The UV absorbance of fMet-Leu-Phe and metabolites were 
measured at 210 nm. For the portal vein blood collection, 2 Ci/ml (0.1 M) [3H-Phe] 
fMet-Leu-Phe was perfused in the jejunum of wild-type mice for 90 min. The portal vein 
blood was collected during the period of 80-90 min. The whole blood was centrifuged at 
3,300 g for 3 mins. 100 l plasma was then extracted by adding 200l of acetonitrile. 
The supernatant was further condensed by SpeedVac concentrator SVC-200H and 
reconstituted into 20l water following by HPLC analysis with 250 x 4.6 mm C18 
column (Discovery®, Supelco, Bellefonte, PA) and Packard 500TR radiochemical 
detector (PerkinElmer Life and Analytical Sciences, Boston, MA). 30% acetonitrle plus 
0.1% TFA was used as the mobile phase.    
In situ Single-pass Intestinal Perfusion 
Intestinal perfusion were peformed in wild-type and Pept1 knockout mice 
 
(8-10 
week old) according to previous described (Jappar et al., 2010) In brief, animals were 
fasted overnight and anesthetized with sodium pentobarbital (40-60 mg/kg ip). An 8 cm 
segment was isolated (i.e., ~2 cm distal to the ligament of Treitz). A glass cannula (2.0 
mm outer diameter), attached to Tygon
® 
Laboratory tubing, were inserted at both ends of 
intestinal segment and secured in place with silk sutures. Following cannulation, the 
isolated intestinal segment was rinsed with isotonic saline solution, and covered with 
saline-wetted gauze and parafilm to prevent dehydration. After the surgical procedure, 
the mice were transferred to a temperature-controlled chamber (31
o
C) to maintain the 
body temperature of mice during the experiment. The inlet cannula was connected to a 
30-ml syringe placed on a perfusion pump (Harvard Apparatus, Syringe Infusion Pump 
22, South Natick, MA). 
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The perfusate contained 135 mM NaCl, 5 mM KCl, 10 mM MES (pH 6.5), 0.01% 
[
14
C]inulin, and 0.1 M [3H-Phe] fMet-Leu-Phe in the presence of 0 mM, 25 mM, 50 
mM, 100 mM, ,150 mM phenylalanine was perfused through the jejunum at a rate of 0.1 
ml/min for the inhibitory curve study and 100 mM was used in the rest of experiments 
(concentration dependency, specificity study and the regional dependency). The exiting 
perfusate was collected every 10 mins for 90 mins. A 100 l aliquot of each time point 
was added to a vial containing scintillation fluid (CytoScint
®
, MP Biomedicals, Solon, 
OH) and measured by a dual-channel liquid scintillation counter (Beckman LS 6000 SC, 
Beckman Coulter, Inc, Fullerton, CA). The water flux was corrected by the non-
permeable [
14
C]inulin. For the specificity study, the potential inhibitors were used at 50 
mM. 
Regional Intestinal Permeability 
Four intestinal segments were perfused separately as described above for jejunum. 
For duodenal perfusion, a 2 cm segment was isolated (i.e. ~0.25 cm distal to the pyloric 
sphincter). For jejunal perfusion, an 8 cm segment was isolated (i.e. ~2 cm distal to the 
ligament of Tretiz). For ileal perfusion, a 6 cm segment was isolated (i.e. ~1 cm proximal 
to the cecum). For colonic perfusion, a 3 cm segment was isolated (i.e. ~0.5 cm distal to 
the cecum). 
Effect of in situ Perfusion of fMet-Leu-Phe on the Myeloperoxidase (MPO) Activity 
Gender-matched wild-type and Pept1 knockout mice (8-10 week old) were 
perfused as described above in jejunum and colon with modification. The Krebs-Ringer 
buffer was perfused through the intestinal segment at rate of 0.067 ml/min for jejunum 
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and 0.1 ml/min for colon for 30 min and shifted to Krebs-Ringer buffer containing 0 or 
10 M fMet-Leu-Phe for 4 hours. For inhibition study, 50 mM glycylglycine (Gly-Gly) 
was used. After 4 hour perfusion, the MPO activity was determined by 
spectrophotometric method based on the oxidation of o-dianisidine as previously 
described (Buyse et al., 2002). Briefly, intestinal segment (50-100 mg) was homogenized 
by homogenizer (PowerGen Model 125 Homogenizer, Fisher Scientific, Pittsburgh, PA) 
on ice for 30 seconds in 50 mM potassium phosphate buffer (pH = 6.0) containing 0.5% 
hexadecyltrimethyl ammonium bromide (1 ml / 50-100 mg). After homogenization, 
homogenates were introduced to the freeze-thawed procedure for three times (-80
o
C / 
37
o
C). Then, the homogenates were centrifuged at 12,800 g for 15 mins at 4
o
C. The 
supernatant (0.1 ml) was added to 2.9 ml 50 mM phosphate buffer (pH = 6.0) containing 
0.167 mg/ml (0.53 mM) o-dianisidine dihydrochloride and 0.0005% (0.15 mM) hydrogen 
peroxide. The change of absorbance at 460 nm was measured for 2 mins at 15 s intervals. 
The slope of the change of absorbance was calculated by the kinetics mode of UV/Vis 
spectrophotometer (BU-530
®
 Beckman Coulter
TM
, Fullerton, CA). The myeloperoxidase 
(MPO) activity was reported as IU/g wet tissue. One IU of MPO activity was defined as 
the quantity of enzyme able to convert 1 mol of hydrogen peroxide to water in 1 min at 
room temperature.    
fMet-Leu-Phe Hydrolysis Kinetics by Jejunal Homogenates  
Intestinal homogenates were prepared by scraping off the mucus layers from the 
jejunum by glass slide and homogenated in 0.5 ml ice-cold PBS by homogenator 
(PowerGen Model 125 Homogenizer, Fisher Scientific, Pittsburgh, PA) at speed 2 for 2 
mins on ice. The homogenates were then centrifuged at 12,000 x g for 15 mins. The 
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supernatant was taken and the total protein concentration was measured by the Pierce 
protein assay kit (Thermo Scientific, Rockford, IL). 25 l of 0.5 mg/ml protein were 
taken and incubated with different concentrations of [
3
H-Phe] fMet-Leu-Phe (0.4 M – 
100 M) for 1 min at 37oC. 50 l 10% TFA was then added following by 15,000 x g 
centrifugation for 15 mins. 20 l of the supernatant will be analyzed by HPLC with 250 x 
4.6 mm C18 column (Discovery®, Supelco, Bellefonte, PA) and Packard 500TR 
radiochemical detector (PerkinElmer Life and Analytical Sciences, Boston, MA) using 
30% acetonitrile plus 0.1% TFA as the mobile phase. The rate of hydrolysis was 
calculated by measuring the loss of fMet-Leu-Phe in the supernatant. 
Histological Examination   
Samples after 4 hour perfusion with and without 10 M fMet-Leu-Phe were fixed 
in buffered formalin in a Swiss-roll shape for overnight and embedded in paraffin (3 
wild-type mice ± fMet-Leu-Phe, 3 Pept1 knockout mice ± fMet-Leu-Phe, and 2 wild-type 
mice + fMet-Leu-Phe + Gly-Gly, totally 11 slides). 5 m sections were taken and stained 
with hematoxylin-eosin (H&E) to reveal structural features and examined with light 
microscopy in a blinded manner by a pathologist. 
Data Analysis 
The effective permeability (Peff) was determined by the loss of drug from the 
perfusate at steady-state according to a complete radial mixing (parallel tube) model. 
(Komiya et al., 1980; Kou et al., 1991) 
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In the equation, Q is the flow rate (ml/min), R is the intestinal radius (cm), L is the length 
of intestine (cm), Cout is the outlet drug concentration (corrected for water flux by 
[
14
C]inulin), and Cin is the inlet drug concentration. In current study, the steady-state was 
reached after 30 min perfusion. The steady-state flux (J) was referenced to the intestinal 
wall concentration (Cw) to estimate the intrinsic kinetic parameters (Vmax, Km) after 
factoring out the resistance of the unstirred water layer.  
  
       
     
 
The transformation of the inlet concentration to the intestinal wall concentration was 
based on the equation, where the Paq is the estimated unstirred aqueous permeability 
(Johnson et al., 1988).    
          
    
   
  
The aqueous permeability was determined by following equations. 
      
 
 
         
    
   
  
 
The aqueous diffusion coefficient (D = 3.18 × 10
−4
 cm
2
/min) was calculated by Hayduk-
Laudie expression (Reid et al., 1977). Gz is the Graetz number (0.0399), and A is a 
unitless constant (1.225) estimated by A = 2.5 Gz + 1.125. 
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For the fMet-Leu-Phe hydrolysis study, the hydrolysis kinetic parameters (Vmax, 
Km) were estimated by Michaelis-Menten equation.  
  
      
    
 
In this equation, the V is the hydrolysis rate of fMet-Leu-Phe (nmole/mg/min) and C is 
the concentration of fMet-Leu-Phe (M). 
 Statistical Analysis 
Data were expressed as mean  SE. Two-tailed student’s t-test was used to 
compare difference between two groups. For multiple comparisons, one-way ANOVA 
followed by Dunnett’s or Tukey’s post hoc comparison was used (GraphPad Prism, v5.0; 
GraphPad Software, Inc., La Jolla, CA). A probability of p  0.05 was considered 
significant. Nonlinear regression analyses were performed using GraphPad Prism 
software, where the goodness of fit was determined by the coefficient of determination 
(r
2
), the standard error of parameter estimates, and visual inspection of the residuals.  
 
 
 
 
 
 
 
 
 
 74 
 
RESULTS 
Intestinal Metabolism of fMet-Leu-Phe and Exposure in Portal Vein  
The metabolic pattern was determined by directly incubating fMet-Leu-Phe in 
different intestinal segments. As shown in Fig. 3.1A-D, the hydrolysis of fMet-Leu-Phe 
was highest in the duodenum, followed by jejunum, ileum and colon, with the major 
metabolite being phenylalanine. During perfusion with [
3
H-Phe]fMet-Leu-Phe for 90 min, 
only phenylalanine was detectable in the blood of portal vein (Fig. 3.1E). These results 
are consistent with a previous paper, where they suggested fMet-Leu-Phe would be 
completely metabolized after passing through the intestinal membrane (Woodhouse et al., 
1987).  The results also demonstrate that while f-Met-Leu is formed as a metabolite, the 
dipeptide Leu-Phe is not.  This is important as it allows an accurate assessment of fMet-
Leu-Phe permeability when studied in the presence of unlabelled Phe (as shown later).   
Regional Intestinal Permeability 
To determine whether fMet-Leu-Phe was a substrate of PEPT1 and if differences 
existed in its permeability between intestinal segments, fMet-Leu-Phe was perfused in the 
duodenum, jejunum, ileum, and colonof both wild-type and Pept1 knockout mice. Since 
fMet-Leu-Phe was metabolized in the intestine as shown in Fig. 3.1A-D, the forming 
metabolite, [
3
H]Phe would confound the results by being taken up through other 
transporter systems. By adding excess non-radiolabeled Phe, the confounding effect can 
be  eliminated. As shown in Fig. 3.2, the effective permeability decreased when 
increasing the concentration of non-radiolabeled Phe, and showed completely inhibition 
around 100 mM. Therefore, perfusing fMet-Leu-Phe in the presence of 100 mM non-
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radiolabeled Phe was used as  a standard condition for the remaining experiments. In the 
presence of 100 mM non-radiolabeled  Phe, the effective permeability was measured in 
both small and large intestines of wild-type and Pept1 knockout mice. As shown in Fig. 
3.3, the effective permeability of fMet-Leu-Phe was considerably lower in duodenum, 
jejunum, and ileum of Pept1 knockout mice as compared to that of wild-type mice. 
However, the permeability of fMet-Leu-Phe was very low and similar in the colon of 
both genotypes. When comparing the results among intestinal segments, there was no 
difference between all four segments of Pept1 knockout mice. By contrast, the 
permeability of fMet-Leu-Phe in wild-type mice was higher in duodenum and jejunum 
following by ileum (40% lower) and colon (98% lower).  . These findings were similar to 
our previous results  with Gly-Sar, a model dipeptide substrate for PEPT1 (Jappar et al., 
2010).   
Specificity Studies 
The specificity of fMet-Leu-Phe uptake was examined in jejunum of both wild-
type and Pept1 knockout mice by adding the known PEPT1 substrate glycylproline (Gly-
Pro) and the known PHT1/PHT2 substrate L-histidine. By co-perfusing the PEPT1 
substrate Gly-Pro in the jejunum of both genotypes , the effective permeability of fMet-
Leu-Phe was reduced in wild-type mice but not in Pept1 knockout mice (Fig. 3.4). In 
contrast, L-histidine showed no effect on the effective permeability of fMet-Leu-Phe in 
both genotypes(Fig. 3.4), which suggested PHT1/PHT2 have no contribution on the 
transport of fMet-Leu-Phe in jejunum.  
Concentration Dependency Study   
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To examine whether the uptake of fMet-Leu-Phe was saturable, the permeability 
of fMet-Leu-Phe was measured over the concentration range 0.1 M – 7.5 mM. As 
shown in Fig. 3.5, fMet-Leu-Phe exhibited a nonlinear uptake and the intrinsic Vmax and 
Km values (i.e., after correcting for the unstirred water layer) were estimated by 
nonlinear regression. After fitting the data to a single-term Michaelis-Menten equation, a 
Vmax of 0.73 ± 0.07 nmole/cm
2
/s and Km of 1.6 ± 0.37 mM were obtained. This Km 
value was comparable to a previous study, where a Km value of 2.9 mM was reported in 
the KG-1 cell line (Charrier et al., 2006a). 
Effect of in situ Perfusion of fMet-Leu-Phe on Myeloperoxidase (MPO) activity 
It has been shown previously in rats that MPO activity increased when perfusing 
10 M fMet-Leu-Phe in the intestine (Buyse et al., 2002). The results of MPO activity 
after fMet-Leu-Phe perfusion in jejunum of wild-type mice were shown as Fig. 3.6A, 
which showed a comparable result to previous studies in rat. Perfusing 10 M fMet-Leu-
Phe for 4 hours in the jejunum of wild-type mice increased the MPO activity around 2-
fold. The increase of MPO activity could be abolished by adding the dipeptide 
glycylglycine (50 mM), thereby inhibiting the PEPT1-mediated uptake of fMet-Leu-Phe. 
In contrast, this phenomenon was not observed when perfusing 10 M fMet-Leu-Phe in 
the jejunum of Pept1 knockout mice for 4 hours, suggesting that fMet-Leu-Phe was not 
being transported into enterocytes in the absence of PEPT1 (Fig. 3.6B). Likewise, there 
was no MPO activity increase when perfusing 10 M fMet-Leu-Phe in the colon of both 
genotypes for 4 hours (Fig. 3.6C). Interestingly, the baseline MPO activity between wild-
type mice and Pept1 knockout mice in colon showed no difference. The MPO activity of 
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wild-type mice was 3-fold higher than that of Pept1 knockout mice, although all values in 
colon were much lower than that in jejunum. 
fMet-Leu-Phe Hydrolysis Kinetics in Jejunal Homogenates 
The hydrolysis of fMet-Leu-Phe in both wild-type and Pept1 knockout mice were 
examined using jejunal homogenates. The hydrolysis rate exhibited nonlinear kinetics 
with increasing fMet-Leu-Phe concentrations. As shown in Fig. 3.7, the hydrolysis curves 
of wild-type and Pept1 knockout mice were virtually superimposable. The estimated 
intrinsic kinetic parameters, obtained from nonlinear regression analyses, showed no 
difference between wild-type and Pept1 knockout mice. Vmax values of 3.2 ± 0.23 and 3.3 
± 0.12 nmole/mg/min (p = 0.66), and Km values of 7.0 ± 2.4 and 6.9 ± 1.2 M (p = 0.968) 
were obtained for wild-type and Pept1 knockout mice, respectively.  
Histological Examination  
The H & E staining showed no significantly difference across samples with 
different treatments. All of the slides showed neutrophils within the submucosa and 
infiltrating the muscularis externa to varying degrees. Inflammation was qualitatively 
similar across groups and there were only minor differences in intensity between samples 
(Table 3.1). No significant differences in villus shape and no true villus blunting were 
observed (Figure 3.9). 
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DISCUSSION 
The importance and the specificity of PEPT1-mediated transport of di/tripeptides 
in intestinal segments were previously shown by single-pass intestinal perfusions in 
Pept1 knockout mice (Jappar et al., 2010). The effective permeability of a hydrolysis-
resistant dipeptide, Gly-Sar, was significantly reduced in the intestine of mice lacking 
PEPT1 expression. In the current study, PEPT1-mediated transport of a bacterially-
produced peptide, fMet-Leu-Phe, was demonstrated directly by measuring its effective 
permeability in mouse intestine. The effective permeability of fMet-Leu-Phe in wild-type 
mice was significant higher than that of Pept1 knockout mice in all segments of small 
intestine (i.e. duodenum, jejunum, and ileum), except for colon. The residual 
permeability of fMet-Leu-Phe in mice lacking PEPT1 expression was only 5-17% of 
values in mice with PEPT1 expression, suggesting that PEPT1 was the main transporter 
responsible for fMet-Leu-Phe transport in small intestine. In addition, the difference of 
effective permeability of fMet-Leu-Phe along the entire intestine was consistent with the 
protein expression of PEPT1 in the intestine, with higher and comparable values in 
duodenum and jejunum, followed by the ileum, and little to none permeability in colon, 
which was consistent with Gly-Sar uptake in our previous results (Jappar et al., 2010).   
The potential contribution of PHT1/PHT2 in the transport of fMet-Leu-Phe in 
intestine was examined in the jejunum of both genotypes. In the presence of L-histidine, a 
known substrate of PHT1/PHT2, the effective permeability of fMet-Leu-Phe in jejunum 
was not changed in both wild-type and Pept1 knockout mice. Although the expression of 
PHT1 in the apical membrane in jejunum has been suggested (Bhardwaj et al., 2006), its 
contribution to the transport of fMet-Leu-Phe was not significant as compared to PEPT1. 
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 The concentration dependency of fMet-Leu-Phe transport was evaluated in the 
jejunum of wild-type mice. Although the curve did not fully reach a plateau due to 
solubility limitations of fMet-Leu-Phe in our buffer, the nonlinear transport of fMet-Leu-
Phe was clear with estimates of Km = 1.6 ± 0.37 mM and Vmax = 0.73 ± 0.07 
nmole/cm
2
/s. Our Km value was comparable to a previous report in cell culture (Charrier 
et al., 2006a) and to Km values for PEPT1 in the literature for various compounds such 
as cefadroxil and cephalexin (Sinko et al., 1988), which suggested that PEPT1 was a low-
affinity transporter.  
 Our findings have shown that perfusion of fMet-Leu-Phe in the jejunum induced 
the activity of myeloperoxidase, which implied that fMet-Leu-Phe can be transported into 
the enterocytes through PEPT1 transporter. This finding was in contradiction to another 
report (Woodhouse et al., 1987) in which the authors claimed that fMet-Leu-Phe would 
be non-permeable to intestinal membranes due to the combination of hydrolysis enzymes 
and intrinsic membrane barrier. Our results clearly showed that fMet-Leu-Phe can be 
transported into enterocytes along the entire small intestine, but not in colon, and that 
PEPT1 was the main transporter contributing to this transport (Fig. 3.3). Interestingly, 
when using carboxypeptidase inhibitors, 25 mM benzylsuccinic acid (BzS) or 10 mM 
EDTA, as in the previous paper (Woodhouse et al., 1987), the permeability of Gly-Sar in 
jejunum was significantly reduced (1.7 x 10
-4
 cm/s for control, 0.21 x 10
-4
 cm/s for BzS, 
0.69 x 10
-4
 cm/s for EDTA, n=3, Fig. 3.8). Our results suggested that carboxypeptidase 
inhibitors such as BzS and EDTA would compromise the transport activity of PEPT1 
leading to the false conclusion that fMet-Leu-Phe was non-permeable to intestinal 
membranes. . 
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The perfusion of 10 M fMet-Leu-Phe in jejunum and colon in both wild-type 
and Pept1 knockout mice demonstrated that PEPT1 was involved in the dynamic 
consequence of increasing MPO activity. In Fig. 5A, the increased MPO activity was 
reduced after co-perfusing fMet-Leu-Phe with the PEPT1 substrate Gly-Gly, which 
showed no effect on MPO activity when being perfused alone. In Pept1 knockout mice 
(Fig. 3.5B), perfusion of fMet-Leu-Phe failed to result in a similar increase of MPO 
activity. Both results suggested that without PEPT1 transporter, fMet-Leu-Phe would not 
be transported into the enterocytes to increase MPO activity. However, when perfusing 
fMet-Leu-Phe in the colon of both genotypes, no increase of MPO activity was observed, 
which was consistent the fact that little or no PEPT1 was expressed in colon. 
Interestingly, the baseline activity of MPO between wild-type and Pept1 knockout mice 
showed a small but significant difference in colon. However, the difference may be due 
to experimental variation since the measured activity was very low as compared to 
jejunum. Alternatively, it may be due to the contribution of very low but undetectable 
PEPT1 expression in the colon. More experiments will be needed to clarify this 
unexpected result.   
In was important to rule out any possible differences of hydrolysis enzymes 
between wild-type and Pept1 knockout mice, especially if a reduced permeability and 
unchanged MPO activity after fMet-Leu-Phe perfusion in Pept1 knockout mice were due 
to an increased hydrolysis activity after genetic knockout of PEPT1. For this reason, 
fMet-Leu-Phe hydrolysis kinetics was examined in both wild-type and Pept1 knockout 
mice.  In this study, we found no difference between wild-type and Pept1 knockout mice 
in the intrinsic kinetic parameters, Vmax and Km. In the current study, specific enzymes 
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contributing to the hydrolysis of fMet-Leu-Phe were not evaluated only the nonspecific 
process. . Although the responsible enzymes for the hydrolysis of fMet-Leu-Phe were 
uncertain, one category of enzymes was reported to be responsible for the hydrolysis of 
fMet-Leu-Phe, that being carboxypeptidase (Chadwick et al., 1990). According to the 
literature (depending on the specific isoform, compound, and experimental system), the 
Km of carboxypeptidases can range from 6 to 1573 M (Deiteren et al., 2007). The low 
Km value of 7 μM in our study is consistent with these literature values. Moreover, the 
metabolite pattern of fMet-Leu-Phe intestinal degradation agrees with carboxypeptidases 
being responsible for the hydrolysis of fMet-Leu-Phe. In this regard, the major metabolite 
of fMet-Leu-Phe was Phe, suggesting that the direction of hydrolysis was from the 
carboxyl terminus (Fig. 3.1A-D).  
Colonic PEPT1 has been suggested to be involved in intestinal inflammation 
based on the results of direct and indirect data such as: 1) the upregulation of PEPT1 in 
the apical membrane of patients with inflammatory bowel disease; 2) increasing amounts 
of bacteria in the colons of patients with inflammatory bowel disease (Swidsinski et al., 
2002);  this was confirmed by some animal colitis models (Hernandez et al., 2003); 3) the 
ability of PEPT1 to transport bacterial compounds; 4) immune cells, such as 
macrophages, have been shown to express PEPT1 on their surface; and 5) a genetic 
polymorphism study demonstrating the possibility of PEPT1 being involved in 
inflammatory bowel disease (Zucchelli et al., 2009); still, the results showed the 
influence of PEPT1 in two opposite directions (risk and protection).  Interestingly, an 
alternate hypothesis was proposed by the same group in which the possible role of PEPT1 
in intestinal inflammation was investigated by studies in wild-type and hPEPT1 
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transgenic mice after citrobacter rodentium infection (Nguyen et al., 2009). Surprisingly, 
PEPT1 transgenic mice showed less inflammatory responses due to the presence of fewer 
bacteria adhesion on colonic membranes. These studies demonstrate the very complex 
nature of inflammation and IBD in which the environment, genetics, immunology, 
microbiome, and diet may all play an important role. More thoughtful/creative studies 
will be needed in order to elucidate the role of colonic PEPT1 in intestinal inflammation.  
In conclusion, the present studies provide several new findings: 1) PEPT1 can 
transport bacterially-produced peptide fMet-Leu-Phe with comparable permeability in the 
duodenum and jejunum of mice, followed by ileum; there is little to no transport in colon ; 
2) the transport of fMet-Leu-Phe in mouse small intestine was specific for PEPT1; 3) the 
estimated intrinsic Km of fMet-Leu-Phe was 1.6 mM; 4) PEPT1 was responsible for the 
increased MPO activity in jejunum after perfusion of fMet-Leu-Phe; and 5) the 
hydrolysis of fMet-Leu-Phe was  unchanged after genetic knockout of PEPT1 in mice. 
 
 
 
 
 
 
 
 83 
 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Chromatogram of metabolites of fMet-Leu-Phe after incubation with 1 cm 
intestinal segments of wild-type mice for 5 min at 37
o
C and metabolites in the portal vein 
plasma after in situ perfusion for 90 mins. (A) duodenum (B) jejunum (C) ileum (D) 
colon (E) portal vein plasma. Phe: phenylalanine, f-Met: formyl-methionine, f-Met-Leu: 
formyl-methionyl-leucine, fMet-Leu-Phe: N-formyl-methionyl-leucyl-phenylalanine. 
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Figure 3.2. Effective permeability of fMet-Leu-Phe in jejunum of wild-type mice in the 
presence of phenylalanine at different concentrations (Mean ± SE, n=3). Groups with 
different letters represented statistical difference which performed by one-way ANOVA 
with Tukey’s comparison. 
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Figure 3.3. Effective permeability of fMet-Leu-Phe in different intestinal segments of 
wild-type mice and Pept1 knockout mice in the presence of 100 mM phenylalanine 
(Mean ± SE, n=6). Groups with different letters represented statistical difference which 
performed by one-way ANOVA with Tukey’s comparison for the same genotype and by 
t-test between different genotypes for each intestinal segment.     
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Figure 3.4. Gly-Pro (50 mM) inhibited the effective permeability of fMet-Leu-Phe in the 
jejunum of wild-type mice (A) but not in that of Pept1 knockout mice (B)  (Mean ± SE, 
n=4).  L-histidine (50 mM) showed no inhibitory effects in the jejunum of both wild-type 
and Pept1 knockout mice (Mean ± SE, n=4). Statistical analysis was performed by one-
way ANOVA with Dunnett’s analysis as compared to control. * p < 0.05. 
 
 
 
 
(B) KO 
(A) Wild-type 
 87 
 
0 1 2 3 4
0.0
0.2
0.4
0.6
fMet-Leu-Phew (mM)
U
p
ta
k
e
 R
a
te
 (
n
m
o
l/
c
m
2
/s
)
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Concentration dependency of fMet-Leu-Phe uptake in the jejunum of wild- 
type mice (Mean ± SE, n=4). fMet-Leu-Phew was referenced to the estimated 
concentration at intestinal wall.    
Michaelis-Menten   
Best-fit values   
Vmax 0.7314 
Km 1.551 
Std. Error   
Vmax 0.07031 
Km 0.3666 
95% Confidence Intervals   
Vmax 0.5879 to 0.8750 
Km 0.8028 to 2.300 
Goodness of Fit   
Degrees of Freedom 30 
R² 0.9645 
Absolute Sum of Squares 0.03697 
Sy.x 0.03511 
Constraints   
Km Km > 0.0 
Number of points   
Analyzed 32 
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Figure 3.6. (A) fMet-Leu-Phe induced MPO activity and Gly-Gly (50 mM) reversed the 
fMet-Leu-Phe-induced MPO activity in the jejunum of wild-type mice (Mean ± SE, n=5). 
(B) fMet-Leu-Phe-induced MPO activity was not observed in the jejunum of Pept1 
knockout mice (Mean ± SE, n=5). (C) fMet-Leu-Phe showed no effects in the colon of 
both wild-type and Pept1 knockout mice (Mean ± SE, n=5). Groups with different letters 
represented statistical difference which performed by one-way ANOVA with Tukey’s 
comparison. 
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Figure 3.7. fMet-Leu-Phe hydrolysis kinetics by jejunal homogenates of wild-type and 
Pept1 knockout mice (Mean ± SE, n=4). The data were fitted to Michaelis-Menten 
equation. 
 
 
Michaelis-Menten WT  KO 
Best-fit values     
Vmax 3.200 3.318 
Km 7.027 6.918 
Std. Error     
Vmax 0.2327 0.1223 
Km 2.355 1.179 
95% Confidence Intervals     
Vmax 2.718 to 3.683 3.065 to 3.572 
Km 2.143 to 11.91 4.472 to 9.364 
Goodness of Fit     
Degrees of Freedom 22 22 
R² 0.8602 0.9593 
Absolute Sum of Squares 5.012 1.403 
Sy.x 0.4773 0.2526 
Constraints     
Km Km > 0.0 Km > 0.0 
Number of points     
Analyzed 24 24 
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Figure 3.8. Effective permeability of Gly-Sar were affected in the presence of the 
inhibitor of carboxypeptidase BzS and EDTA (Mean ± SE, n=3). 
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Figure 3.9. Representative photomicrographs of jejunum of experimental groups. A. 
wild-type control. B, F. Pept1 knockout control. C. wild-type + fMet-Leu-Phe. D. Pept1 
knockout + fMet-Leu-Phe . E. wild-type + fMet-Leu-Phe + Gly-Gly) . A-E: original 
magnification (x200), bars = 100 m. Insets (x1800). F. original magnification (x600), 
bar = 20 m. 
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Chapter 4 
 
IMPACT OF INTESTINAL PEPT1 ON THE REGIONAL PERMEABILITY OF 
LYS-PRO-VAL, AN ANTI-INFLAMMATORY TRIPEPTIDE DERIVED FROM 
-MELANOCYTE-STIMULATING HORMONE 
 
ABSTRACT 
Lys-Pro-Val, which is derived from -melanocyte-stimulating hormone (-MSH), 
has been shown to possess anti-inflammatory activity and suggested to be a novel 
therapeutic agent for inflammatory diseases.  Although studies suggested that Lys-Pro-
Val is transported by the PEPT1 transporter, no direct measurement of intestinal 
permeability has been performed.  In addition, the intestinal stability of Lys-Pro-Val has 
not been addressed. In the present study, intestinal homogenates were used to study the 
stability of Lys-Pro-Val in different intestinal regions of wild-type mice. The effective 
permeability of [
3
H-Pro]Lys-Pro-Val in duodenum, jejunum, ileum, and colon was 
determined by single-pass intestinal perfusions in wild-type and Pept1 knockout mice. 
Based on stability studies, the intrinsic clearances (CLint) of Lys-Pro-Val were associated 
with the mRNA expression of two intestinal peptidases, namely dipeptidyl peptidase IV 
(DPPIV) and aminopeptidase P (APP). Therefore, two peptidase inhibitors (Phe- 
Pyrrolidide and o-phenathroline) were incorporated in the perfusion experiments.
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Compared with wild-type mice, Pept1 knockout mice exhibited greater than 90% 
reduction in Lys-Pro-Val uptake in all small intestinal segments, but showed no 
difference in colon. Lys-Pro-Val uptake was significantly inhibited by dipeptide and 
cefadroxil in duodenum, jejunum and ileum, but not colon. Lys-Pro-Val exhibited 
nonlinear uptake kinetics with an estimated Km of 0.11 mM (based on Cwall) and a 
nonsaturable component in the jejunum of wild-type mice. The findings demonstrated 
that PEPT1 played a critical role in the uptake of Lys-Pro-Val in small intestines and 
suggested that the stability of Lys-Pro-Val was a significant concern when using Lys-Pro-
Val as a therapeutic agent, especially after oral administration.   
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INTRODUCTION 
-Melanocyte-stimulating hormone (-MSH) has been known to exert different 
biological activity in addition to its pigmentary activity for decades. The anti-
inflammatory effect of -MSH was one of the bioactivities that received the most interest. 
Many studies have been performed to elucidate the required pharmacophore of -MSH to 
interact with melanocortin receptors, which indicated that the core peptide histidine-
phenylalanine-arginine-tryptophane (HFRW, -MSH6-9) was responsible for binding. 
Upon binding to melanocortin receptors, -MSH exerts its anti-inflammatory effect 
mainly by inhibiting the activation of NF-B through an increase of intracellular cAMP 
(Manna et al., 1998). Although -MSH demonstrated promising anti-inflammatory effect, 
the major concern for practical use was its melanotropic effect. Therefore, more attention 
focused on the C-terminal tripeptide of -MSH and its related derivatives, such as KPV, 
KdPVand KPT, which have been shown to retain the anti-inflammatory activity of -
MSH with no significant melanotropic effect. The anti-inflammatory activity of tripeptide 
KPV and its derivatives have been demonstrated by both in vitro and in vivo models. For 
example, KPV demonstrated a similarly effective suppression of LPS/IFN--induced NF-
B activation and NO production as full-length -MSH in the RAW 264.7 murine 
macrophage cell line (Mandrika et al., 2001). After an intracerebroventricular (i.c.v.) 
injection of lipopolysaccharide (LPS), mice, pretreated with 200 mg i.p. KPV showed a 
reduction of NF-B activation (Ichiyama et al., 1999).  In another study, dextran sodium 
sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) was used to induce colitis after 
which 100 uM KPV was added to the drinking water and mice allowed to drink the water 
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ad libitum. Most interesting, the results showed that KPV was able to reduce the mRNA 
of IL-6 and IL-12 in the DSS model and to effectively decrease the mRNA of IL-1, IL-6, 
TNF-, and IFN- in the TNBS model, all proinflammatory cytokines (Dalmasso et al., 
2008).   
PEPT1 transporter belongs to the solute carrier 15 family (SLC15), which consists 
of four mammalian members, including the high-capacity, low-afﬁnity peptide 
transporter 1 (PEPT1; SLC15A1), the low-capacity, high-afﬁnity transporter PEPT2 
(SLC15A2), and the peptide/histidine transporters PHT1 (SLC15A4) and PHT2 
(SLC15A3). PEPT1 is expressed throughout the small intestine (duodenum, jejunum, and 
ileum), but with little or no expression in the colon. Immunofluorescent staining also 
showed that PEPT1 was expressed mainly at the apical side of the enterocyte with 
decreasing expression from the tip to the crypt of the villus (Ogihara et al., 1996). Studies 
suggested that PEPT1 was very important for nutrition aspect because it facilitated the 
absorption of digested protein in the form of di/tripeptides (Ganapathy et al., 2006). 
Besides having nutritive relevance, PEPT1 was also important for the uptake of some 
peptidomimetics, such as -lactam antibiotics (Okano et al., 1986), valacyclovir 
(Ganapathy et al., 1998), ACE inhibitors (Thwaites et al., 1995), and bestatin (Tomita et 
al., 1990). 
Although the bioactive tripeptide Lys-Pro-Val has been shown to be a substrate 
for PEPT1 in Caco-2 cells (Dalmasso et al., 2008), no direct measurement of its intestinal 
permeability has been done before. As a potential therapeutic for inflammatory bowel 
disease, intestinal permeability is an important property to understand. The single-pass 
intestinal perfusion technique is a useful tool to determine the effective permeability of 
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drug in intestines. By using this perfusion method in wild-type and Pept1 knockout mice, 
it has been successfully demonstrated that PEPT1 was responsible for the uptake of a 
hydrolysis-resistant dipeptide, Glycylsarcosine (Gly-Sar) in duodenum, jejunum, and 
ileum (Jappar et al., 2010). Therefore, the objective for the current study was to 
determine the regional effective permeability of [
3
H-Pro]Lys-Pro-Val in small and large 
intestines by using Pept1 knockout mice and in doing so, provide more rational results 
for evaluating whether or not intestinal PEPT1 might be a good target for KPV.   
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MATERIALS AND METHODS 
Materials 
[
3
H-Pro] Lys-Pro-Val (40 Ci/mmol) was purchased from AmBios Labs, Inc 
(Newington, CT). [
14
C] inulin (2.38 mCi/g) was purchased from MP Biomedicals (Solon, 
OH). GlycylProline (Gly-Pro), Lys-Pro-Val (KPV; -MSH11-13), and Phe-pyrrolidide 
were obtained from Bachem, Inc (Torrance, CA). All other chemicals were acquired from 
Sigma-Aldrich (St. Louis, MO). 
Animals   
Mouse experiments were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the U.S. National Institutes of Health. 
Gender-matched wild-type and Pept1 knockout mice (8-10 week old) were used in all the 
experiments. The mice were kept under a 12-hr light and 12-hr dark cycle, and fed ad 
libitum with standard diet and water (Unit for Laboratory Animal Medicine, University of 
Michigan, Ann Arbor, MI).   
Lys-Pro-Val Hydrolysis Kinetics by Intestinal Homogenates   
Intestinal homogenates were prepared by scraping off the mucus layers from the 
segments of interest by glass slide and homogenated in 0.5 ml ice-cold PBS by tissue 
homogenator (PowerGen Model 125 Homogenizer, Fisher Scientific, Pittsburgh, PA) at 
speed 2 for 2 min on ice. The homogenates were then centrifuged at 12,000 x g for 15 
min. The supernatant was taken and the total protein concentration was measured by the 
Pierce protein assay kit (Thermo Scientific, Rockford, IL). 50 l of 0.5 mg/ml protein 
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were taken and incubated with 50 l of Lys-Pro-Val (final concentration = 1 mM) for 
different time points (5, 10, 20, 30, and 50 min) at 37
o
C. 10 l 10% TFA was added to 
stop the enzymatic reaction and samples were filtered with 0.2 m filter and centrifuged 
at 5,000 x g for 3 mins. 55 l of the supernatant were analyzed by HPLC with C18 
column (Symmetric®, Waters, Milford, MA). Mobile phase consists of A: 0.1 mM 
NaH2PO4/H2O and B: 100% Acetonitrile. A gradient flow was used, starting from 100% 
buffer A for 3 mins and changed to 60% buffer A and 40% buffer B over 15 mins. The 
UV absorbance of KPV was measured at 214 nm. The amount of Lys-Pro-Val being 
hydrolyzed was calculated by measuring the loss of Lys-Pro-Val in the supernatant and 
expressed as the percentage of remaining (%) of original.  
Regional Intestinal Permeability of [
3
H-Pro]Lys-Pro-Val    
10 M [3H-Pro]Lys-Pro-Val was perfused in intestinal segments of wild-type and 
Pept1 knockout mice (8-10 week old). Animals were fasted overnight and anesthetized 
with sodium pentobarbital (40-60 mg/kg ip). Four intestinal segments were isolated and 
perfused simultaneously as follows: A 2 cm duodenum was isolated (i.e. ~0.25 cm distal 
to the pyloric sphincter), an 8 cm jejunum was isolated (i.e., ~2 cm distal to the ligament 
of Treitz), a 6 cm ileum was isolated (i.e. ~1 cm proximal to the cecum), and a 3 cm 
colon was isolated (i.e. ~0.5 cm distal to the cecum). Glass cannula (2.0 mm outer 
diameter), attached to Tygon
® 
Laboratory tubing, were inserted at both ends of intestinal 
segments and secured in place with silk sutures. Following cannulation, the isolated 
intestinal segment was rinsed with isotonic saline solution, and covered with saline-
wetted gauze and parafilm to prevent dehydration. After the surgical procedure, the mice 
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were transferred to a temperature-controlled chamber (31
o
C) to maintain the body 
temperature of mice during the experiment. The inlet cannula was connected to a 30-ml 
syringe placed on a perfusion pump (Harvard Apparatus, Syringe Infusion Pump 22, 
South Natick, MA). The perfusate contained 135 mM NaCl, 5 mM KCl, 10 mM 
MES/Tris (pH 6.5), 0.01% [
14
C]inulin, 10 M [3H-Pro]Lys-Pro-Val, 5 mM Phe-
pyrrolidide, and 0.25 mM o-phenanthroline was perfused through the intestinal segments 
at a rate of 0.1 ml/min, and in the inhibition studies, the perfusate contained 25 mM 
inhibitors (L-histidine, L-proline, Gly-Pro, Cefadroxil, TEA) in the solution above. For 
pH dependency studies, pH was adjusted by different ratio between 10 mM MES/Tris 
and 10 mM HEPES/Tris buffer. The effective permeability of Lys-Pro-Val was measured 
over a range of pH (5.0 - 7.5) in different intestinal segments. A Na
+
/H
+
 inhibitor, 
dimethyl amiloride (DMA) at 2 mM was also used to examine the pH dependency of 
Lys-Pro-Val transport in jejunum. For concentration dependency study, 0.01, 0.1, 0.5, 1, 
2.5, 5, 7.5, 10, 20, 30 mM Lys-Pro-Val were perfused at pH 6.5. 
mRNA Expression of Dipeptidyl Peptidase IV (DPPIV) and Aminopeptidase P (APP) 
in Wild-type and Pept1 Knockout Mice.     
Quantification of DPPIV and APP transcripts were carried out in different 
intestinal segments from wild-type mice and Pept1 knockout mice using the 7300 Real-
Time PCR System (Applied Biosystems, Foster City, CA). The total mRNA was isolated 
using an RNeasy Plus Mini Kit (QIAGEN, Valencia, CA) and then reverse-transcribed 
using Omniscript® reverse transcription kit (QIAGEN, Valencia, CA). Primers and 
probes were designed by Primer Express 3.0 software (Applied Biosystems, Foster City, 
CA), and all the primers, probes were synthesized by Integrated DNA Technologies, Inc. 
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(Coralville, IA). The forward and reverse primers for DPPIV and APP were 5’-
CGGTCTGCCCCTCTACACTCT-3’, 5’-TTCCAGGACTCGCAGCTCTT-3’, and 5’-
AGCTGCACAAGGAAGTTAGCATT-3’, 5’-GCCCACGTTCTGTCCATCA-3’, 
respectively. The forward and reverse primers for glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were 5’-GAGACAGCCGCATCTTCTTGT-3’, 5’-
CACACCGACCTTCACCATTTT-3’, respectively. Quantitative polymerase chain 
reaction (qPCR) was performed with SYBR green system (Applied Biosystems, Foster 
City, CA). The thermal profile was 1 cycle at 50°C for 2 mins, 1 cycle at 95°C for 10 
mins, 40 cycles at 95°C for 15 s, and 60°C for 1 min.  
Portal vein Exposure of Lys-Pro-Val during Perfusion 
For the portal vein blood collection, 8.6 Ci/ml (10 M) [3H-Pro]Lys-Pro-Val 
was perfused in the jejunum of wild-type mice for 90 mins with/ without peptidase 
inhibitors at condition above. The portal vein blood was collected during the period of 
80-90 min. The whole blood was centrifuged at 3,300 g for 3 mins. 500l of acetonitrile 
was added to 250 l plasma and centrifuged at 15,000 x g for 5 mins for extraction. The 
supernatant was further condensed by SpeedVac concentrator SVC-200H and 
reconstituted into 20l water following by HPLC analysis with 250 x 4.6 mm C18 
column (Discovery®, Supelco, Bellefonte, PA) and Packard 500TR radiochemical 
detector (PerkinElmer Life and Analytical Sciences, Boston, MA). 5% acetonitrle with 
0.1% TFA was used as the mobile phase.    
Data Analysis  
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(1) 
The first order rate constant of hydrolysis, k, were estimated by fitting the data to 
the equation. 
            
Y: percentage of remaining at time t (%), k: hydrolysis constant (1/minute), t: time 
(minute) and CLint: apparent intrinsic clearance (l/min/mg protein) were calculated by 
the formula. 
      
                         
                              
   
The relative amount of DPPIV and APP transcripts to GAPDH transcripts were by 
following formula. 
                                            
The effective permeability (Peff) was determined by the loss of drug from the perfusate at 
steady-state according to a complete radial mixing (parallel tube) model. (Komiya et al., 
1980; Kou et al., 1991) 
     
                
    
 
In the equation, Q is the flow rate (ml/min), R is the intestinal radius (cm), L is the length 
of intestine (cm), Cout is the outlet drug concentration (corrected for water flux by 
[
14
C]inulin), and Cin is the inlet drug concentration. In current study, the steady-state was 
reached after 30 min perfusion. The steady-state flux (J) was referenced to the inlet drug 
concentration (Cin) to estimate the kinetic parameters (Vmax’, Km’) as shown in eq.5. 
(2) 
(3) 
(4) 
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The intrinsic parameter (Vmax and Km) were also estimated after factoring out the 
resistance across the unstirred water layer, where the steady-state flux (J) was referenced 
to intestinal wall concentration (Cw) as shown in eq. 6. 
  
       
     
      
 
The flux in eqs. 5 and 6 were modeled using a single saturable process (i.e., Michaelis-
Menten), and a single saturable process plus a linear term respectively. All kinetic 
parameters were then estimated by nonlinear regression (GraphPad Prism, v5.0; 
GraphPad Software, Inc., La Jolla, CA).  
The transformation of the inlet concentration to the intestinal wall concentration was 
based on the equation, where the Paq is the estimated unstirred aqueous permeability 
(Johnson et al., 1988).    
          
    
   
  
The aqueous permeability was determined by following equations. 
      
 
 
         
    
   
  
 
(6) 
(5) 
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The aqueous diffusion coefficient (D = 3.60 × 10
−4
 cm
2
/min) was calculated by Hayduk-
Laudie expression (Reid et al., 1977). Gz is the Graetz number (0.0452), and A is a 
unitless constant (1.238) estimated by A = 2.5 Gz + 1.125. 
Statistical Analysis  
Data were expressed as mean  SE. Two-tailed student’s t-test was used to 
compare difference between two groups. For multiple comparisons, one-way ANOVA 
followed by Dunnett’s or Tukey’s post hoc comparison was used (GraphPad Prism, v5.0; 
GraphPad Software, Inc., La Jolla, CA). A probability of p  0.05 was considered 
significant. Nonlinear regression analyses were performed using GraphPad Prism 
software, where the goodness of fit was determined by the coefficient of determination 
(r
2
), the standard error of parameter estimates, and visual inspection of the residuals.  
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RESULTS 
Lys-Pro-Val Hydrolysis Kinetics by Intestinal Homogenates    
Lys-Pro-Val (1 mM) was incubated with homogenates prepared from different 
intestinal segments at 37
o
C in PBS. The data showed that Lys-Pro-Val was least stable in 
the ileum following by jejunum, but relatively stable in duodenum and colon (Fig. 4.1). 
The half-life of Lys-Pro-Val was 20 and 29 min, respectively, for ileum and jejunum 
(duodenum and colon were less than 5% degraded over 50 min). The calculated intrinsic 
clearance for ileum and jejunum were 153 and 105 l/min/mg, respectively.          
Regional Intestinal Permeability of Lys-Pro-Val   
Since radiolabel was on the proline position in the current study, metabolites such 
as Lys-Pro (KP), Pro-Val (PV), or Pro (P) would affect the accuracy of permeability 
results. For this reason, we elected to inhibit the formation of potential degradation 
metabolites of the tripeptide.  Our results demonstrate that co-perfusing KPV with the 
peptidase inhibitors  Phe-pyrrolidide (5 mM) and o-phenathroline (0.25 mM) would 
successfully prevent the degradation of Lys-Pro-Val during the perfusion in Pept1 
knockout mice (Fig. 4.2A). Therefore, the regional intestinal perfusion studies were 
performed under the same conditions. As shown in the results (Fig. 4.2B), the effective 
permeability of Lys-Pro-Val in the small intestines (duodenum, jejunum, and ileum) of 
wild-type mice were significantly greater than that of Pept1 knockout mice, which 
showed 13-fold, 21-fold, and 19-fold difference in duodenum, jejunum, and ileum, 
respectively. This finding suggested that PEPT1 contributed to greater than 90% of the 
uptake of Lys-Pro-Val in all segments of the small intestine, with negligible contribution 
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from either paracellular or passive routes. . In contrast, the colon showed no difference in 
the effective permeability of Lys-Pro-Val between genotypes. When comparing the 
effective permeability of Lys-Pro-Val between different small intestinal segments of 
wild-type mice, no significant differences were However, the effective permeability of 
Lys-Pro-Val  in duodenum, jejunum or ileum showed 18- to 22-fold greater values than 
that in colon. 
Specificity Studies  
 The specificity of KPV transport was examined in four intestinal segments by co-
perfusing glycylproline (Gly-Pro) and cefadroxil (known PEPT1 substrates), L-histidine 
(a known PHT1/PHT2 substrate), L-proline (a known PAT1 substrate), and TEA (a 
known OCT substrate). In the presence of Gly-Pro and cefadroxil, the effective 
permeability of Lys-Pro-Val decreased by about 50-90% in duodenum, jejunum, and 
ileum. No decrease was observed in the colon for both compounds. Moreover, no 
inhibitory effect was noted when co-perfusing KPV with L-histidine, L-proline, or TEA, 
suggesting that PHT1/2, PAT1, or OCT did not contribute to the uptake of Lys-Pro-Val.  
Thus, it appears that PEPT1 was the main transporter responsible for the uptake of Lys-
Pro-Val in small intestine (Fig. 4.3).  
Concentration Dependency Study 
The uptake of Lys-Pro-Val was studied across a wide range of perfusate 
concentrations (0.01-30 mM). As shown in Fig. 4.4A, the uptake was nonlinear and, 
when fitted to a single Michaelis-Menten term, had kinetic parameters of Vmax’ = 2.4 ± 
0.2 nmole/cm
2
/s and Km’ = 14.7 ± 1.9 mM by (r2 = 0.974). When referencing Lys-Pro-
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Val to estimated intestinal wall concentrations, and fitting the data to a single Michaelis-
Menten term and linear component, the intrinsic kinetic parameters were Vmax = 0.83 ± 
0.08 nmole/cm
2
/s, Km = 0.11 ± 0.06 mM, and Kd = 0.0456 ± 0.007 cm/s (r
2
 = 0.891) 
(Fig. 4.4B). 
pH Dependency Studies and DMA Inhibition  
Because PEPT1 has been known as a proton-coupled transporter, the proton 
gradient might influence the activity of PEPT1 transport. However, the results showed 
that there was no significant pH dependency among the four intestinal segments (Fig. 4.7 
A-D). Furthermore, the Na
+
/H
+
 exchanger inhibitor DMA, at high concentration (2 mM), 
showed no significant effect on the effective permeability in the jejunum of wild-type 
mice(Fig. 4.7E).   
Relative mRNA Expression of DPPIV and APP between Genotypes   
Two intestinal peptidases were hypothesized to be responsible for the metabolism 
of Lys-Pro-Val in the intestinal lumen, namely DPPIV and APP since they are thought as 
proline-specific enzymes. In the presence of two inhibitors for DPPIV and APP, the Lys-
Pro-Val degradation was completely inhibited as shown in Fig. 4.2A. However, since the 
experiment was performed in Pept1 knockout mice, we were concerned that expression 
of these two peptidases might be different between wild-type and Pept1 knockout mice. . 
We tested this possibility and as shown in Fig. 4.5, the mRNA expression of both DPPIV 
and APP were not significantly different between the two genotypes in all intestinal 
segments. Although the mRNA expression of both enzymes for Pept1 knockout mice was 
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somewhat higher in ileum as compared to wild-type mice, the results were not 
statistically different (n=6 replicates). 
Portal Vein Exposure of Lys-Pro-Val during Perfusion  
Chromatograms of perfusate in wild-type mice, with and without peptidase 
inhibitors, supported our contention that hydrolysis activity was completely inhibited in 
the presence of peptidase inhibitors (Fig. 4.8). The presence of intact Lys-Pro-Val in the 
portal vein was also examined during the perfusion of 10 M Lys-Pro-Val.   As shown, 
all the Lys-Pro-Val was completely degraded during the transepithelial transport in 
jejunum since no detectable intact [
3
H-Pro]Lys-Pro-Val was found in plasma from the 
portal vein (Fig. 4.9).  
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DISCUSSION 
In this study, the intestinal stability of Lys-Pro-Val was examined for the first 
time by using intestinal homogenates. The data demonstrated that Lys-Pro-Val was 
unstable in jejunum and ileum, but stable in duodenum and colon over 50 min. (Fig. 4.1). 
The peptidases for the hydrolysis were probably dipeptidyl peptidase IV (DPPIV) and 
aminopeptidase P (APP) because they are both proline-specific enzymes. The regional 
activity of these two peptidases has been reported in rat, where the activity is highest in 
ileum ~ jejunum > jejunoileal junction > duodenum > cecum for DPPIV and the activity 
is highest in jejunoileal junction ~ ileum > cecum ~ duodenum ~ jejunum for APP (Bai, 
1994). Our hydrolysis data with Lys-Pro-Val were in agreement with that of Bai (1994), 
in which the ileum had the highest hydrolysis activity. Meanwhile, the mRNA expression 
of DPPIV and APP were examined in both wild-type and Pept1 knockout mice. There 
was no difference between the two genotypes in all intestinal segments, which showed 
the highest expression in ileum, following by jejunum, duodenum, and colon. The mRNA 
expression results were also consistent with the hydrolysis results from our intestinal 
homogenate studies demonstrating that ileum and jejunum were the major segments for 
Lys-Pro-Val hydrolysis. In order to minimize the influence of peptidases when 
performing perfusion experiments, two peptidase inhibitors were used in our perfusate 
(Phe-pyrrolidide for DPPIV and o-phenathroline for APP). At the concentration of 5 mM 
phe-pyrrolidide and 0.25 mM o-phenathroline, the effective permeability of Gly-Sar was 
not compromised (Fig. 4.6) and showed completely inhibition of hydrolysis in the 
perfusion study of Pept1 knockout mice and wild-type mice (Fig. 4.2A and Fig. 4.8). In a 
previous study using the single-pass intestinal perfusion technique, the effective 
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permeability of Gly-Sar was significantly decreased in the absence of PEPT1 in small 
intestine, thereby demonstrating the importance and specificity of PEPT1 in transporting 
the hydrolysis-resistant dipeptide, Gly-Sar (Jappar et al., 2010). In the present study, the 
intestinal permeability of Lys-Pro-Val, an -MSH related tripeptide, was directly 
measured using the single-pass intestinal perfusion technique. As shown in our results, 
the effective permeability of Lys-Pro-Val was dramatically reduced in Pept1 knockout 
mice as compared to that of wild-type mice in the small intestines. PEPT1 contributed at 
least 90% of the total uptake of Lys-Pro-Val in the small intestine, demonstrating that 
PEPT1 was the main transporter responsible for transport of the tripeptide. In contrast, 
the effective permeability of Lys-Pro-Val showed no difference between wild-type and 
Pept1 knockout mice in colon, which agrees with the fact that PEPT1 has little to no 
expression in the colon (Fig. 4.2B). The specificity of Lys-Pro-Val was examined by co-
perfusing the PEPT1 substrates Gly-Pro and cefadroxil, and the effective permeability 
decreased in all three small intestinal segments, further supporting that PEPT1 was 
responsible for the uptake of Lys-Pro-Val in these segments (Fig. 4.3). 
PEPT1 was characterized as a high-capacity and low-affinity transporter. The 
reported Km for PEPT1 ranged from 0.1 – 15 mM depending on the substrate, tissue cell 
types, experimental systems, conditions and data analysis (Fei et al., 1994; Brandsch et 
al., 2004). The uptake of Lys-Pro-Val was studied with escalating concentrations in this 
study and the estimated intrinsic Km value was 0.11 ± 0.058 mM after factoring out the 
influence of the unstirred aqueous layer. The Km of KPV in our study was comparable to 
that previously reported in CaCo2-BBE cells (i.e., Km = 0.16 mM) and the Jurkat cells 
(i.e., Km = 0.7 mM) (Dalmasso et al., 2008), suggesting that Lys-Pro-Val has a relatively 
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high affinity for PEPT1. The nonsaturable component (Kd) contributed only 0.6% to the 
total transport of KPV under linear conditions range, which also agrees with the data 
from Pept1 knockout mice demonstrating that PEPT1 contributed at least 90% of the 
total uptake of Lys-Pro-Val in small intestine (Fig. 4.2B). Taken it as a whole, PEPT1 
was the major transporter responsible for the uptake of Lys-Pro-Val in small intestines 
and has a relatively high affinity for (Km = 0.11 mM) this POT protein. 
The contribution of PHT1/PHT2 in the transport of Lys-Pro-Val in small and 
large intestines was examined in severa segments of wild-type mice. In the presence of L-
histidine, a known substrate of PHT1/PHT2, the effective permeability of Lys-Pro-Val 
was not changed in duodenum, jejunum, ileum or colon. . Although the expression of 
PHT1 in the apical membrane of jejunum has been suggested (Bhardwaj et al., 2006), its 
contribution to the transport of Lys-Pro-Val was not apparent. . Contribution of other 
transporters was also examined, including that of PAT1 and OCT. In the presence of L-
proline, a known substrate of PAT1, the effective permeability of Lys-Pro-Val showed no 
difference, suggesting that PAT1 was not responsible for the uptake of Lys-Pro-Val in 
small intestine. Since Lys-Pro-Val would bear a net positive charge in the pH of our 
condition (pH 6.5), the contribution of organic cation transport was also studied. We 
found that TEA had no effect on the permeability of KPV, suggesting that OCTs did not 
contribute to the uptake of Lys-Pro-Val in small intestine.             
A lack of pH dependency was observed in our study (Fig. 7 A-D). This finding is 
most likely due to the fact that changes in bulk pH might not translate into changes in 
microclimate pH (Hogerle et al., 1983). Surprisingly, when adding 2 mM DMA, an 
inhibitor of the Na
+
/H
+
 exchanger, the effective permeability still showed no difference. 
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This lack of change might be due to the concentration of DMA not being high enough 
since DMA is a more selective inhibitor of NHE1 and NHE2;only at very high 
concentration (3 mM), did DMA show an inhibitory effect on NHE3 (Furukawa et al., 
2004). A similar lack of effect on PEPT2 activity by inhibitors of Na
+
/H
+
 exchange has 
also been reported in the human nasal epithelium (Agu et al., 2011). It suggested that the 
uptake of dipeptide was driven by proton pump rather than Na
+
/H
+
 exchanger in their 
system. In addition, membrane potential has been suggested to be more important than 
pH as for the driving force of PEPT1 (Weitz et al., 2007).   
Like Lys-Pro-Val, there are several other bioactive peptides that have been 
reported in the literature such as carnosine (-alanyl-L-histidine), anserine (-alanyl-1-N-
methyl-L-histidine) (Tan et al., 1998), Ile-Pro-Pro, and Val-Pro-Pro (Foltz et al., 2007). 
Although they are all substrates for PEPT1 transport conceptually due to their 
di/tripeptide structure, a study demonstrated that the major absorptive mechanism of Val-
Pro-Pro was paracellular transport (Satake et al., 2002). Another study focusing on the 
pharmacophore of PEPT1 suggested that not all the di/tripeptides were substrates of 
PEPT1 (Vig et al., 2006). Therefore, it is important to understand the transport 
mechanism of bioactive peptides, especially after their oral administration. Another 
concern for bioactive peptides is their in vivo stability. Our intestinal homogenate studies 
showed that Lys-Pro-Val was not very stable during its transepithelial transport across the 
epithelial membrane (Fig. 4.1). Depending on the target disease, some formulation 
techniques might be the way to overcome this hydrolysis issue. For example, a 
nanoparticle loaded with Lys-Pro-Val was designed to achieve local delivery to its site of 
action in the colon (Laroui et al., 2010). The data showed that a 12,000-fold lower of 
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dose could achieve a similar effect. The reason for this nanoparticle formulation being 
effective might be due to the colonic PEPT1 expression under inflammatory conditions 
increasing the uptake of Lys-Pro-Val, but also protection of Lys-Pro-Val by the 
formulation against high peptidase activity along the intestine.  
A final point is that the Lys-Pro-Val used in this study was in a free acid form 
with no acetylation at the N-terminal. However, in the literature, some of the -MSH 
related peptides (e.g., KPV, KdPV, KdPT) were N-acelylated and C-amidated peptides 
(Hiltz et al., 1991) while others were not (Getting et al., 2003). Although no comparison  
has been made for the  N-acelylated and C-amidated forms of the Lys-Pro-Val on anti-
inflammatory effect, it has been known that N-acelylated and C-amidated substrates 
might affect their affinity to PEPT1 (Meredith et al., 2000). Since PEPT1 has been shown 
to transport Lys-Pro-Val in both this and previous studies, its intracellular concentration 
in the target cell (e.g. epithelial cell or macrophage) could be affected by the form of 
actual compound that is used. Therefore, systematic experiments on the structure-activity 
relationship of the Lys-Pro-Val (and derivatives) and effects on pharmacokinetics are 
worth pursuing.           
In conclusion, our findings provided valuable insight on the intestinal transport of 
a new -MSH related tripeptide. First, Lys-Pro-Val was least stable in the ileum 
following by jejunum, and relatively stable in the duodenum, and colon. To become a 
promising therapeutic agent, strategies such as nanoparticle formulations might be 
needed to protect against potential hydrolysis in the intestine after oral dosing. Second, 
PEPT1 was the main transporter responsible for the uptake of Lys-Pro-Val in small 
intestine, but not colon. However, systematic pharmacokinetic/ pharmacodynamic study 
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of Lys-Pro-Val is worth conducting, particularly in the case of oral administration. 
Finally, the utilization of Pept1 knockout mice successfully demonstrated the importance 
of PEPT1 in the absorption of Lys-Pro-Val.  Future studies should look to evaluate the 
importance of PEPT1 in disease models of inflammatory bowel disease, and potential 
therapeutic interventions. 
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Figure 4.1. The hydrolysis of Lys-Pro-Val by intestinal homogenates (Mean ± SE, n=3). 
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Figure 4.2. (A) Co-perfusion of peptidase inhibitors (5 mM Phe-pyrrolidide and 0.25 
mM o-phenathroline) demonstrated completely inhibition of hydrolysis of Lys-Pro-Val 
during perfusion in the Pept1 knockout mice (Mean ± SE, n=3). (B) Regional 
permeability of Lys-Pro-Val in wild-type mice and Pept1 knockout mice (Mean ± SE, 
n=6). * < 0.05, ** < 0.01,*** <0.001 as compared to each wild-type segment by student’s 
t-test. 
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Figure 4.3. PEPT1 substrates (Gly-Pro and Cefadroxil) inhibited the effective 
permeability of Lys-Pro-Val in three small intestinal segments, but not in colon. Substrate 
of PHT1/2, L-histidine, substrate of organic cation transporter, TEA, and substrate of 
PAT1 transporter, L-Proline showed no inhibition in all intestinal segments (Mean ± SE, 
n=4). The concentration of all inhibitors was 25 mM. Statistical analyses were performed 
by one-way ANOVA with Dunnett’s comparison against control within each segment. 
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Figure 4.4. Concentration dependency of Lys-Pro-Val uptake in the jejunum of wild-type 
mice (Mean ± SE, n=3-4). (A) as reference to the inlet concentration which modeled by a 
single Michaelis-Menten equation. (B) as reference to the estimated concentration at 
intestinal wall which modeled by a single Michaelis-Menten plus a linear term.  
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Figure 4.5. mRNA expression of DPPIV and APP in the intestinal segments in both 
genotypes (Mean ± SE, n=6). 
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Figure 4.6. Effective permeability of GlySar was influence by peptidase inhibitors at 
high concentrations (Mean ± SE, n=4-6). Statistical analyses were performed by one-way 
ANOVA with Dunnett’s comparison against control within each segment (* <0.05, ** 
<0.01). 
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Figure 4.7. (A-D) pH dependency of Lys-Pro-Val transport in different intestinal 
segments (Mean ± SE, n=4). (E) Influence of DMA to the transport of Lys-Pro-Val in the 
jejunum of wild-type mice (Mean ± SE, n=4). 
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Figure 4.8. Chromatogram of [
3
H-Pro]Lys-Pro-Val during the perfusion of jejunum in 
wild-type mice. (A) Control, (B) Outlet perfusate without peptidase inhibitors, (C) Outlet 
perfusate with peptidase inhibitors. 
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(B) Outlet perfusate in absence of peptidase inhibitors, at 50 min 
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(C) Outlet perfusate in the presence of peptidase inhibitors, at 50 min 
(A) Control: Lys-Pro-Val standard 
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Figure 4.9. Chromatogram of [
3
H-Pro]Lys-Pro-Val in portal vein plasma during the 
perfusion of jejunum in wild-type mice. 
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 Portal vein sample using perfusate in the presence of peptidase inhibitors, at 80-90 min 
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APPENDIX A 
 
 
COMPARISON OF THE SUSCEPTIBILITY TO DEXTRAN SODIUM SULFATE 
BETWEEN WILD-TYPE AND PEPT1 KNOCKOUT MICE 
 
 
OBJECTIVE   
In order to examine the impact of the speculated colonic PEPT1 under intestinal 
inflammation situation, DSS colitis model was used to study the influence of colonic 
PEPT1 in the progress of colitis.    
MATERIALS AND METHODS 
Dextran sodium sulfate (DSS) (Avg. MW = 40,000; MP biomedicals, Solon, OH) 
colitis model was used to investigate the difference of susceptibility after genetic PEPT1 
knockout. Colitis was induced by two different treatment schedules: (1) adding 3% DSS 
(wt/vol) in the drinking water for 8 days in both wild-type and Pept1 knockout mice; (2) 
adding 3% DSS (wt/vol)  in the drinking water for 5 day following by recovery for 1 or 2 
weeks in both wild-type and Pept1 knockout mice. The progress of colitis will be 
monitored by daily examination of weight loss, gross bleeding, and the presence of loose 
stools or diarrhea for the calculation of the disease activity index (DAI) (Cooper et al., 
1993) (Table A.1). After treatment, colon samples were collected and divided into parts. 
One part is for the determination of the myeloperoxidase activity as previous described 
(Chapter 2) and the other part was for the measurement of mRNA expression of 
cytokines, chemokines, and the mRNA and protein expression of PEPT1. 
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RESULTS  
Acute 8 day Treatment of 3%DSS 
Both wild-type and Pept1 knockout mice started to show significant weight loss 
as compared to their tap water control groups on day 5 after the DSS challenge (Fig. A.1). 
Comparing between genotypes, the weight loss showed statistical difference after 5-day 
treatment of 3% DSS, however, the disease activity index (DAI), which calculated by the 
clinical outcome criteria showed in Table A.1, showed difference on day 5, day 6, and 
day 8 (Fig. A.2). When comparing the indicators of intestinal inflammation, the 
myeloperoxidase activity (MPO) increased 6-8 fold after 8 day treatment of DSS in colon. 
However, there was no significant difference between genotypes (Fig. A.3). In contrast, 
the MPO activity showed no increase in the jejunum of wild-type and Pept1 knockout 
mice (Table A.3). All of the mice (6/6 in both genotypes) treated with DSS developed 
clinical sign of colitis, such as diarrhea and bloody stool, and none of them died on day 8 
of treatment (Table A.3). For the mRNA expression of pro-inflammatory cytokines, such 
as TNF-, IL-1, IL-12B, IL-6, showed increase to various degrees (some would not 
reach statistical difference, however the increase was apparent). Only IFN- showed no 
increase in both wild-type and Pept1 knockout mice. Most importantly, there were no 
significant differences observed between two genotypes in any of the pro-inflammatory 
cytokine expression after day 8 of DSS treatment, suggesting that the severity of 
inflammation was not different between two genotypes (Fig. A.4). Same kind of trends 
were also observed in either chemokines or anti-inflammatory cytokines after DSS 
treatment in both genotypes, which were induction of chemokines (Cxcl2 and KC) and 
pro-inflammatory cytokine, IL-10 within genotypes but no significant difference between 
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genotypes (Fig. A.5 and A.6).  Taken as a whole, colitis was successfully induced by the 
treatment of DSS in both wild-type and Pept1 knockout mice. However, there was no 
significant difference of degree of severity observed between two genotypes.  
PEPT1 Expression after 8 day Treatment   
The mRNA and protein level of PEPT1 were checked by real-time PCR and 
western blot. The results showed that under the colitis situation, the mRNA of PEPT1 in 
colon decrease significantly (Fig. A.12A). The protein of PEPT1 was not detectable after 
the induction of colitis (Fig. A.12B), suggesting that PEPT1 might not be induced under 
this treatment.  
5 day 3%DSS Treatment with Recovery   
According to previous paper (Radeva et al., 2007), which demonstrated by 
immunohistochemistry that PEPT1 ectopically expressed in distal colon after DSS 
treatment, the treatment consisted of challenge phase and recovery phase. Both wild-type 
and Pept1 knockout mice were then treated in similar schedule, which was 5 day 
treatment of 3% DSS following by 1 or 2 weeks recovery. In this kind of treatment, both 
wild-type and Pept1 knockout mice started to show significant weight loss on day 6 after 
the DSS challenge and started to gain weight after day 9 (reached the trough on day 9). 
Comparing between genotypes, the weight loss patterns showed no significant difference 
over the recovery phase although Pept1 knockout mice showed a little more decrease in 
average, but not reach statistical significance (Fig. A.7). When comparing the indicators 
of intestinal inflammation, the myeloperoxidase activity (MPO) stay slightly higher than 
control after 1 week recovery and return to normal on week 2 in wild-type mice (Fig. 
A.8). Surprisingly, in Pept1 knockout mice, after 2 week recovery, the MPO activity was 
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still higher than control (Fig. A.8). Although it might indicate more severe colitis 
occurred in Pept1 knockout mice, the mRNA expression of pro-inflammatory cytokines, 
chemokines, and anti-inflammatory cytokines did not support the result. The mRNA 
expression of TNF-, IL-1, IL-12B, IL-6, and IFN- showed increase to various degrees 
(some would not reach statistical difference, however the increase was apparent) after 
week 1 and remained high after week 2, indicating that although the weight of mice fully 
recovered, the colon was still under inflammatory status. Most importantly, there were no 
significant differences observed between two genotypes in any of the pro-inflammatory 
cytokine expression after week 1 and 2, suggesting that the severity of inflammation was 
not different between two genotypes (Fig. A.9). Similar trends were also observed in both 
chemokines and anti-inflammatory cytokines after DSS treatment in both genotypes, 
which were induction of chemokines (Cxcl2 and KC) and pro-inflammatory cytokine, IL-
10 within genotypes at week 1 and 2, but no significant difference between genotypes 
(Fig. A.10 and A.11).  To summarize, inflammation was persistent after 1 or 2 weeks 
recovery although the challenge of 3% DSS was removed on day 5 in both wild-type and 
Pept1 knockout mice, however, the no significant difference of degree of severity has 
been shown between two genotypes in the recovery phase.   
Pept1 Expression during the Recovery Phase  
In order to check the presence of the ectopically expressed of PEPT1 in colon 
during the recovery phase, mRNA and protein of PEPT1 were examined. The results 
showed that neither mRNA nor protein changed during the recovery phase (Fig. A.13). 
The mRNA remained similar level as compared to control and the protein was still 
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undetectable, which suggesting that the little (or undetectable by western blot) ectopically 
expression of PEPT1 did not contributed significant enough for the inflammation.       
DISCUSSION 
Although the aberrant expression of PEPT1 has been suggested to be involved in 
the pathogenesis of inflammatory bowel disease because of the ability to transport the 
bacterially-produced peptides (Charrier et al., 2006), there was no significant difference 
on the susceptibility to DSS between wild-type and Pept1 knockout mice. Both 
genotypes mice developed colitis after treatment of 3% DSS in both schedules. The 
expression of mRNA and protein might suggested that the lack of difference between 
genotypes was because the ectopic expression of PEPT1 (if any) was not accumulated 
significantly enough to contribute to the inflammation and therefore different colitis 
models might be needed. 
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Figure A.1. Percentage of body weight loss after 3% DSS treatment in wild-type and 
Pept1 knockout mice over time (Mean ± SE, n=6). Statistical analyses were performed by 
student’s t-test (* denoted DSS vs. control of wild-type; # denoted DSS vs. control of 
Pept1 knockout mice; + denoted DSS between genotypes; * p< 0.05, ** p< 0.01, *** p < 
0.001, etc.). 
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Figure A.2. The disease activity index (DAI) after treatment of 3% DSS in wild-type and 
Pept1 knockout mice
 
over time (Mean ± SE, n=6). Statistical analyses were performed by 
student’s t-test (++ p< 0.01; +++ p< 0.001 between genotypes).  
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Figure A.3. The myeloperoxidase (MPO) activity after 3% DSS treatment for 8 days in 
wild-type mice and Pept1 knockout mice (Mean ± SE, n=5). Statistical analyses were 
performed by student’s t-test (* denoted DSS vs. control of wild-type; # denoted DSS vs. 
control of Pept1 knockout mice).  
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Figure A.4. mRNA expression of different cytokines in wild-type and Pept1 knockout 
mice treated with 3% DSS for 8 days (Mean ± SE, n=3-6). Statistical analyses were 
performed by student’s t-test. (A) TNF-, (B) IL-1, (C) IL-6, (D) IL-12B(E) IFN  
(* denoted DSS vs. control of wild-type; # denoted DSS vs. control of Pept1 knockout 
mice).   
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Figure A.5. mRNA expression of different chemokines between wild-type and Pept1 
knockout mice after treatment of 3% DSS for 8 days (Mean ± SE, n=3-6). Statistical 
analyses were performed by student’s t-test. (A) Cxcl2, (B) KC (* denoted DSS vs. 
control of wild-type; # denoted DSS vs. control of Pept1 knockout mice).   
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Figure A.6. mRNA expression of different anti-inflammatory cytokines between wild-
type and Pept1 knockout mice after treatment of 3% DSS for 8 days (Mean ± SE, n=3-6). 
Statistical analyses were performed by student’s t-test.  (A) IL-10, (B) TGF- (* denoted 
DSS vs. control of wild-type; # denoted DSS vs. control of Pept1 knockout mice).   
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Figure A.7. Percentage of weight loss after 5-day 3% DSS treatment and recovered for 1 
or 2 weeks in wild-type mice (solid circle: control, slide triangle: DSS) and Pept1 
knockout mice (open circle: control, open triangle: DSS) (Mean ± SE, n=6-12 in each 
group). 
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Figure A.8. The MPO activity of mice treated with 3% DSS for 5 days and recovered for 
1 or 2 weeks (Mean ± SE, n=5-6). Statistical analyses were performed by one-way 
ANOVA with Dunnett’s comparison against each genotype control (# denoted DSS vs. 
control of Pept1 knockout mice; + denoted DSS between genotypes).  
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Figure A.9. mRNA expression of different cytokines in wild-type and Pept1 knockout 
mice at the recovery phase after treated with 3% DSS for 5 days and recovered for 1 or 2 
weeks (Mean ± SE, n=6). Statistical analyses were performed by one-way ANOVA with 
Dunnett’s comparison against each genotype control. (A) TNF-, (B) IL-1, (C) IL-6, (D) 
IL-12B(E) IFN-(* denoted DSS vs. control of wild-type mice).   
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Figure A.10. mRNA expression of different chemokines in wild-type and Pept1 
knockout mice at the recovery phase after treated with 3% DSS for 5 days and recovered 
for 1 or 2 weeks (Mean ± SE, n=6). Statistical analyses were performed by one-way 
ANOVA with Dunnett’s comparison against each genotype control.  (A) Cxcl2, (B) KC 
(# denoted DSS vs. control of Pept1 knockout mice).   
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Figure A.11. mRNA expression of different anti-inflammatory cytokines in wild-type 
and Pept1 knockout mice at the recovery phase after treated with 3% DSS for 5 days and 
recovered for 1 or 2 weeks (Mean ± SE, n=6). Statistical analyses were performed by 
one-way ANOVA with Dunnett’s comparison against each genotype control (A) IL-10, 
(B) TGF-.  (* denoted DSS vs. control of wild-type mice; # denoted DSS vs. control of 
Pept1 knockout mice).   
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Figure A.12. PEPT1 expression in colon after 3% DSS treatment for 8 days. (A) mRNA 
expression showed decrease after 8 days DSS treatment (Mean ± SE, n=3-6). Statistical 
analyses were performed by student’s t-test. (B) PEPT1 protein expression showed no 
increase in either proximal or distal colon after 8 days DSS treatment. 
 
 
WT 
Prox. Colon 
H2O   DSS 
 
WT 
Dist. Colon 
H2O   DSS 
 
KO 
Jejunum 
H2O  
 
WT 
Ileum 
H2O 
 
(B) 
 148 
 
Control + 1 wk + 2 wks Control + 1 wk + 2 wks
0
100
200
300
400
WT
KO
P
e
p
t1
/G
A
P
D
H
 (
x
1
0
-4
)
R
e
la
ti
v
e
 a
b
u
n
d
a
n
c
e
(A)
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.13. PEPT1 expression in colon at the recovery phase after 3% DSS treatment 
for 5 days. (A) mRNA expression show slight decrease at 1 week recovery, but return to 
normal after 2 weeks of treatment (Mean ± SE, n=6). (B) PEPT1 protein expression 
showed no up-regulation at 1 or 2 weeks recovery after treatment of 5 days DSS.  
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Table A.1. The clinical criteria of scoring system for colitis progress (Adopted from 
Cooper HS et al., 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Weight loss Stool consistency Occult/gross bleeding
0 None Normal Normal
1 1-5%
2 5-10% Loose stools Hemoccult +
3 10-20%
4 > 20% Diarrhea Gross bleeding
The Disease Activity Index (DAI) is the combined scores of weight loss, 
stool consistency, and bleeding divided by 3
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Table A.2. Primers for the real-time PCR analysis of cytokines and chemokines. 
 
 
 
 
 
 
 
 
 
 
Oligonucleotide sequences
36B4 sense 5'-TCC AGG CTT TGG GCA TCA-3'
36B4 antisense 5'-CTT TAT CAG CTG CAC ATC ACT CAG A-3'
GAPDH sense 5’-GAG ACA GCC GCA TCT TCT TGT-3’
GAPDH antisense 5’-CAC ACC GAC CTT CAC CAT TTT-3’
TNF- sense 5'-AGG CTG CCC CGA CTA CGT-3'
TNF- antisense 5'-GAC TTT CTC CTG GTA TGA GAT AGC AAA-3'
IL-1 sense 5'-TCG CTC AGG GTC ACA AGA AA-3'
IL-1 antisense 5'-CAT CAG AGG CAA GGA GGA AAA-3'
IL-6 sense 5'-ACA AGT CGG AGG CTT AAT TAC ACA-3'
IL-6 antisense 5'-TTG CCA TTG CAC AAC TCT TTT C-3'
IL-12B sense 5'-GGA AGC ACG GCA GCA GAA TA-3'
IL-12B antisense 5'-AAC TTG AGG GAG AAG TAG GAA TGG-3'
IFN- sense 5'-CAG CAA CAG CAA GGC GAA A-3'
IFN- antisense 5'-CTG GAC CTG TGG GTT GTT GAC-3'
IL-10 sense 5'-CAG CCG GGA AGA CAA TAA CTG-3'
IL-10 antisense 5'-CGC AGC TCT AGG AGC ATG TG-3'
TGF- sense 5'-GAG GTC ACC CGC GTG CTA-3'
TGF- antisense 5'-TGT GTG AGA TGT CTT TGG TTT TCT C-3'
CCL5 sense 5'-GCA GTC GTG TTT GTC ACT CGA A-3'
CCL5 antisense 5'-GAT GTA TTC TTG AAC CCA CTT CTT CTC-3'
KC sense 5'-TTG TGC GAA AAG AAG TGC AG-3'
KC antisense 5'-TAC AAA CAC AGC CTC CCA CA-3'
Primers used for real-time PCR
Genes
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Table A.3.  Clinical signs of DSS-induced colitis and MPO activity in wild-type and 
Pept1 knockout mice at day 8 of DSS treatment (Mean ± SE, n=6 in each group; Mean ± 
SE, n=5 for MPO activity).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT + Water WT + 3% DSS KO + Water KO + 3% DSS
Clinical signs
Diarrhea 0/6 6/6 0/6 6/6
Bloody stools 0/6 6/6 0/6 6/6
Dead 0/6 0/6 0/6 0/6
MPO activity (IU/g; mean ± SE)
Colon 0.27 ± 0.04 1.52 ± 0.42 0.18 ± 0.04 1.42 ± 0.30
Jejunum 0.71 ± 0.21 0.99 ± 0.27 0.64 ± 0.05 0.78 ± 0.12
**  ** 
 152 
 
 
REFERENCES 
 
Charrier L, Merlin D (2006). The oligopeptide transporter hPepT1: gateway to the innate 
immune response. Lab Invest 86: 538-546. 
 
Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993). Clinicopathologic study of 
dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249. 
 
Radeva G, Buyse M, Hindlet P, Beaufils B, Walker F, Bado A, Farinotti R (2007). 
Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Dig Dis 
Sci 52: 1653-1661. 
 
 
 
153 
 
APPENDIX B 
 
UP-REGULATION OF COLONIC PEPT1 EXPRESSION BY OTHER 
ALTERNATIVE COLITIS MODELS  
 
 
OBJECTIVE  
In order to search for a better model for the study of impact of the aberrant 
colonic PEPT1 to intestinal inflammation, two alternative colitis models were studied, 
which were citrobacter rodentium infection model and IL-10 knockout mice model.   
MATERIALS AND METHODS 
For Citrobacter rodentium infection model, around 6 x 10
10
  cfu/ 100 l bacteria 
was given to animal (FVB) by oral gavage and sterile LB was given for control animals. 
On day 10 of infection, the animals were scarified and small intestine and colon were 
collected for study. For the IL-10 knockout mice model, animals (C57BL/6) were housed 
under SPF environment until the age of 3
+
 months (14 weeks). Wild-type mice were used 
as control (12 weeks). No special diet restriction was applied. Animals were free to both 
food and water and colon of both wild-type and IL-10 knockout mice were collected for 
study.   
RESULTS  
Citrobacter rodentium Infection Model 
Although up-regulation has been shown by infection of Citrobacter rodentium in 
mice ex vivo and in vivo (Nguyen et al., 2009), similar result was not observed in current 
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study. No detectable expression of PEPT1 was observed after infection of Citrobacter 
rodentium for 10 days (Fig. B.1). 
IL-10 knockout Mice Model 
Comparing to wild-type mice, both mRNA (not reach statistical difference but the 
increase was apparent) and protein expression were increased in the colon of IL-10 
knockout mice (Fig. B..2). This result was consistent with previous finding in IL-10 
knockout mice in different strain of mice (129/SvEv), where the up-regulation of PEPT1 
in the colon of IL-10 knockout mice was demonstrated (Chen et al., 2010).   
DISCUSSION 
From appendix A, one potential reason for the lack of difference between wild-
type and Pept1 knockout mice was no enough ectopically expressed PEPT1 accumulated 
in colon. Two other alternative colitis models have been demonstrated to up-regulate 
colonic PEPT1 expression to the detectable level by western blot (Nguyen et al., 2009; 
Chen et al., 2010). Although there were some different experimental settings between 
current study and previous studies, such as the inoculation dose, the sampling time, the 
strain of animals, etc., the IL-10 knockout mice model showed consistent result as 
previously. The colonic PEPT1 expression clearly increased in both mRNA (not reach 
statistical significance) and protein. Therefore, IL-10 knockout would be a better model 
to use to study the impact of the aberrant colonic PEPT1 in the pathogenesis of intestinal 
inflammation or inflammatory bowel disease in the future.       
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FIGURES 
 
 
 
 
 
Figure B.1. The protein expression of PEPT1 after citrobacter rodentium infection. 
 (C: control, T: citrobacter rodentium infection, SI: small intestine). 
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Figure B.2. PEPT1 expression in wild-type and IL-10 knockout mice. (A) mRNA 
expression showed increase but not reached statistical difference between genotypes 
(Mean ± SE, n=3). (B) Protein expression showed significantly increase in IL-10 
knockout mice as compared to wild-type mice (Mean ± SE, n=3). 
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